[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2500
1. Domagała-Kulawik J, Górnicka B, Krenke R, Mich S, Chazan R: The value of cytological diagnosis of small cell lung carcinoma. Pneumonol Alergol Pol; 2010;78(3):203-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of cytological diagnosis of small cell lung carcinoma.
  • INTRODUCTION: Small cell lung carcinoma (SCLC) is a very aggressive neoplasm.
  • The morphology of SCLC cells was not uniform, and often a mixture of non-small atypical cells and bronchial epithelial cells with signs of metaplasia was observed.
  • There were four cases of combined cell type with large cell carcinoma and two with adenocarcinoma.
  • The main diagnostic problem was to distinguish small cell lung carcinoma from lymphomas, and from cancer consisting of small cells with the cytological features of non-small cell carcinoma.
  • In the differential diagnosis, other tumours of small cells have to be taken into account.
  • [MeSH-major] Lung Neoplasms / pathology. Small Cell Lung Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20461688.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Buys TP, Aviel-Ronen S, Waddell TK, Lam WL, Tsao MS: Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma. J Thorac Oncol; 2009 Feb;4(2):227-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma.
  • In the rare case of a male patient presenting with a combined small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma and adenocarcinoma, we used whole genome analysis by tiling-path array comparative genomic hybridization to evaluate the clonal relationship between nodules.
  • The absence of shared genome alteration features for the adenocarcinoma and large cell neuroendocrine carcinoma components suggested that these tumors evolved independently from the SCLC.
  • Taken together, the array comparative genomic hybridization data demonstrate the development and evolution of three independent primary lung cancers in close proximity to each other to form a combined carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Chromosome Aberrations. Genome, Human. Lung Neoplasms / genetics. Neoplasms, Multiple Primary / genetics. Small Cell Lung Carcinoma / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Neuroendocrine / pathology. Comparative Genomic Hybridization. Humans. Immunophenotyping. Male. Microarray Analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179901.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Koutsopoulos AV, Dambaki KI, Datseris G, Giannikaki E, Froudarakis M, Stathopoulos E: A novel combination of multiple primary carcinomas: urinary bladder transitional cell carcinoma, prostate adenocarcinoma and small cell lung carcinoma--report of a case and review of the literature. World J Surg Oncol; 2005 Jul 26;3:51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel combination of multiple primary carcinomas: urinary bladder transitional cell carcinoma, prostate adenocarcinoma and small cell lung carcinoma--report of a case and review of the literature.
  • CASE PRESENTATION: We report a case of a man in whom urinary bladder transitional cell carcinoma, metachronous prostate adenocarcinoma and small cell lung carcinoma were diagnosed within an eighteen-month period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1999 Jan;140(1):150-3 [10215787.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(11-12):678-80 [9620229.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):281-2 [10457131.001]
  • [Cites] Eur J Dermatol. 1999 Sep;9(6):483-6 [10491509.001]
  • [Cites] Clin Exp Dermatol. 2000 Jul;25(5):381-3 [11012589.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):111-4 [11115580.001]
  • [Cites] Hinyokika Kiyo. 2003 May;49(5):261-4 [12822453.001]
  • [Cites] An Med Interna. 1992 May;9(5):257 [1324018.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1992 Aug 21;46(1):53-6 [1330760.001]
  • [Cites] Khirurgiia (Mosk). 1991 Oct;(10):136-43 [1803082.001]
  • [Cites] Am J Clin Oncol. 1991 Feb;14(1):49-51 [1987738.001]
  • [Cites] Eur J Surg Oncol. 1991 Feb;17(1):81-3 [1995363.001]
  • [Cites] Gut. 1979 May;20(5):414-9 [223949.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Nov;26(11):908-12 [2437485.001]
  • [Cites] Gan No Rinsho. 1987 Nov;33(14):1846-53 [2826842.001]
  • [Cites] No Shinkei Geka. 1987 Sep;15(9):1011-7 [2827047.001]
  • [Cites] Gan No Rinsho. 1988 Jul;34(8):1001-5 [3043037.001]
  • [Cites] J Surg Oncol. 1986 May;32(1):8-10 [3724193.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2566-74 [3995473.001]
  • [Cites] Arch Otorhinolaryngol. 1985;242(1):7-12 [4038153.001]
  • [Cites] J Surg Oncol. 1985 Aug;29(4):261-3 [4079408.001]
  • [Cites] J Surg Oncol. 1979;11(1):75-8 [431085.001]
  • [Cites] Cancer. 1974 Apr;33(4):1134-44 [4406171.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1979 Sep;96(9):619-21 [525951.001]
  • [Cites] IMJ Ill Med J. 1982 Feb;161(2):115-6 [6122671.001]
  • [Cites] Arch Pathol Lab Med. 1984 Apr;108(4):272-4 [6546663.001]
  • [Cites] Am J Med. 1983 Feb;74(2):343-8 [6572034.001]
  • [Cites] Arch Dermatol. 1980 Jun;116(6):687-9 [6892866.001]
  • [Cites] Pathol Int. 1994 Apr;44(4):325-32 [8044300.001]
  • [Cites] J Natl Med Assoc. 1994 May;86(5):387-8 [8046769.001]
  • [Cites] Cancer Lett. 1993 Sep 15;73(1):51-7 [8402598.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):452-5 [8425176.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):957-61 [8439970.001]
  • [Cites] Dermatology. 1995;191(4):321-2 [8573931.001]
  • [Cites] Surg Neurol. 1996 Mar;45(3):219-29 [8638217.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):368-73 [8895679.001]
  • [Cites] J Urol. 1997 Jan;157(1):65-7 [8976217.001]
  • [Cites] Pathol Int. 1997 Jan;47(1):68-72 [9051695.001]
  • [Cites] J Urol Nephrol (Paris). 1976 Jul-Aug;82(7-8):621-6 [1034027.001]
  • (PMID = 16045793.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1226150
  •  go-up   go-down


Advertisement
4. Dagnon K, Heudes D, Bernaudin JF, Callard P: Computerized morphometric analysis of microvasculature in non-small cell lung carcinoma. Microvasc Res; 2008 Jan;75(1):112-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized morphometric analysis of microvasculature in non-small cell lung carcinoma.
  • This computerized morphometric study was designed to analyze the distance between cancer cells and blood vessels and microvasculature organization in non-small cell lung carcinoma (NSCLC) comparing squamous cell carcinoma (SCC) and adenocarcinoma (ADC).
  • [MeSH-major] Adenocarcinoma / blood supply. Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Squamous Cell / blood supply. Lung Neoplasms / blood supply. Neovascularization, Pathologic / pathology. Signal Processing, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560614.001).
  • [ISSN] 0026-2862
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


5. Paramez AR, Dixit R, Gupta N, Gupta R, Arya M: Non-small cell lung carcinoma presenting as carcinomatous meningitis. Lung India; 2010 Jul;27(3):158-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung carcinoma presenting as carcinomatous meningitis.
  • Primary bronchogenic carcinoma presenting as carcinomatous meningitis is a very rare occurrence in clinical practice, often occurring during the treatment course of the underlying malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931036.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946719
  • [Keywords] NOTNLM ; Adenocarcinoma lung / carcinomatous meningitis / malignant metastasis
  •  go-up   go-down


6. Sundarraj S, Kannan S: Immunohistochemical expression of cytosolic phospholipase A2α in non-small cell lung carcinoma. Asian Pac J Cancer Prev; 2010;11(5):1367-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of cytosolic phospholipase A2α in non-small cell lung carcinoma.
  • METHODS: We examined cPLA2α expression in normal, premalignant bronchial epithelial cells and nonsmall cell lung carcinoma (NSCLC) samples using an immunohistochemical staining technique.
  • When tumor types were considered, there were more cPLA2α positive adenocarcinomas compared with squamous cell carcinomas (17 of 36 adenocarcinomas (47%) vs. 6 of 34 squamous cell carcinomas (18%); P=0.02).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Group IV Phospholipases A2 / metabolism. Lung Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Biomarkers, Tumor / metabolism. Bronchi / cytology. Carcinoma, Squamous Cell / genetics. Epithelial Cells / cytology. Female. Humans. Macrophages. Male. Middle Aged. Smoking / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198294.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor; EC 3.1.1.4 / Group IV Phospholipases A2
  •  go-up   go-down


7. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II: Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res; 2010 Jan 1;16(1):34-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions.
  • PURPOSE: To identify the pattern of interleukin-1 receptor-associated kinase (IRAK-1) protein expression in non-small cell lung carcinoma (NSCLC) and corresponding preneoplastic lesions.
  • EXPERIMENTAL DESIGN: Archived tissue from NSCLC (adenocarcinoma and squamous cell carcinoma; n = 306) and adjacent bronchial epithelial specimens (n = 315) were analyzed for the immunohistochemical expression of IRAK-1, and the findings were correlated with patients' clinicopathologic features.
  • In adenocarcinoma, combined low level of expression of nuclear IRAK-1 and NF-kappaB correlated significantly with worse overall (HR, 2.485; P = 0.007) and recurrence-free (HR, 3.058; P = 0.006) survivals in stage I/II patients.
  • CONCLUSIONS: IRAK-1 is frequently expressed in NSCLC tissue specimens, and this expression is an early phenomenon in the sequential development of lung cancer.
  • IRAK-1 is a novel inflammation-related marker and a potential target for lung cancer chemopreventive strategies.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Jul 14;477(1-2):73-8 [10899313.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5904-12 [18836471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):71-6 [12559770.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):293-302 [12620219.001]
  • [Cites] Clin Lung Cancer. 2003 Jul;5(1):46-62 [14596704.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):2011-22 [15265936.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6693-7 [1323115.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Curr Opin Immunol. 1999 Feb;11(1):13-8 [10047546.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3468-74 [10416612.001]
  • [Cites] Gene. 2004 Dec 8;343(1):191-201 [15563845.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):744-50 [15720800.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):915-23 [15767370.001]
  • [Cites] J Mol Med (Berl). 2005 Apr;83(4):258-66 [15662540.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1763-75 [16314486.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3796-803 [16517750.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):867-75 [16461741.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):900-5 [16690127.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11194-206 [17145864.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):3-14 [17311529.001]
  • [Cites] BMC Genomics. 2007;8:140 [17540040.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):225-33 [18176604.001]
  • [Cites] Cell Signal. 2008 Feb;20(2):269-76 [17890055.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Mol Cell Biol. 2008 May;28(10):3538-47 [18347055.001]
  • [Cites] FASEB J. 2008 Jul;22(7):2285-96 [18276832.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):861-7 [11309334.001]
  • (PMID = 20028769.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-119004; United States / NCI NIH HHS / CA / P01 CA091844-020002; United States / NCI NIH HHS / CA / P01 CA091844; United States / NCI NIH HHS / CA / CA091844-020002; United States / NCI NIH HHS / CA / P01 CA091844-010002; United States / NCI NIH HHS / CA / P50 CA070907-119004; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / 1P01 CA91844-03; United States / NCI NIH HHS / CA / CA091844-010002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-1; 0 / NF-kappa B; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases
  • [Other-IDs] NLM/ NIHMS155236; NLM/ PMC2811365
  •  go-up   go-down


8. Iyoda A, Hiroshima K, Moriya Y, Yoshida S, Suzuki M, Shibuya K, Yoshino I: Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma. Surg Today; 2010 Aug;40(8):725-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma.
  • PURPOSE: A surgical resection for locally advanced non-small cell lung carcinoma (NSCLC) remains controversial.
  • Age of 70 years or more, tumor length more than 5 cm, lymph node metastases, incomplete resection, and histology of non-adenocarcinoma were significantly associated with an unfavorable prognosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2005 Dec;80(6):2032-40 [16305839.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1745-51; discussion 1751 [12822610.001]
  • [Cites] Ann Thorac Surg. 1999 Oct;68(4):1144-9 [10543470.001]
  • [Cites] Ann Thorac Surg. 2002 Jan;73(1):253-8 [11834019.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1810-4; discussion 1815 [14667588.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):796-802 [11581616.001]
  • [Cites] Ann Thorac Surg. 2001 Apr;71(4):1094-9 [11308142.001]
  • [Cites] Ann Thorac Surg. 1999 Jul;68(1):188-93 [10421139.001]
  • [Cites] Ann Thorac Surg. 2001 Jun;71(6):1759-64 [11426744.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Apr;123(4):670-5 [11986594.001]
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1447-51 [7979673.001]
  • [Cites] Ann Thorac Surg. 2005 May;79(5):1691-6; discussion 1697 [15854956.001]
  • (PMID = 20676855.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


9. Liang ZY, Zeng X, Zhang J, Wu SF, Gao J, Liu TH: [Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):654-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma].
  • OBJECTIVE: To investigate EGFR mutations and gene copy number status in non-small cell lung carcinomas in the Chinese patients.
  • METHODS: Using formalin fixed and paraffin embedded tissue samples, EGFR mutations were investigated in 290 cases of non-small cell lung carcinomas by microdissection and scorpions amplification refractory mutation system.
  • Furthermore, the relationship between EGFR mutations and gene copy number, and the relationship between EGFR gene status and clinicopathological variables of non-small cell lung carcinoma were analyzed.
  • The mutation rates in adenocarcinoma, large cell carcinoma and squamous carcinoma were 48.4%, 16.7% and 0, respectively.
  • FISH positive rates in adenocarcinoma, large cell carcinoma and squamous carcinoma were 52.1%, 75.0% and 11.1%, respectively.
  • Therefore, EGFR mutations mainly occurred in the adenocarcinoma, and was significantly correlated with EGFR high copy number.
  • CONCLUSIONS: There are higher EGFR mutation rate and FISH positive rate in non-small cell lung carcinoma in Chinese patients.
  • Combined analysis of EGFR mutation and gene copy number by FISH may provide a superior approach in selecting patients who may benefit anti-EGFR target therapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Dosage. Genes, erbB-1. Genetic Diseases, Inborn. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094482.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


10. Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, Guo W, Wang Y, Wen D, Wei L, Dong Z, Kuang G: The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis; 2005 Oct;26(10):1748-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma.
  • To assess the effects of the functional single nucleotide polymorphism on cancer susceptibility and progression, the MMP-7 -181A/G genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism analysis among 258 patients with esophageal squamous cell carcinoma (ESCC), 201 patients with gastric cardiac carcinoma (GCA), 243 patients with non-small cell lung carcinoma (NSCLC) and 350 healthy individuals without cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic
  • [MeSH-minor] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Heart Neoplasms / genetics. Humans. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930031.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


11. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Basolo F, Pingitore R, Fontanini G: Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Lung Cancer; 2005 Dec;50(3):309-17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
  • Alterations of p53 suppressor gene are the most common genetic changes found in malignant tumors; several studies examined the link between aberrant p53 and angiogenesis in lung cancer, but only a few studies report data regarding a relation between p53 mutations and IL-8 expression.
  • However, in our samples IL-8 levels did not significantly affect prognosis of NSCLC; more studies are required to elucidate the precise role of IL-8 in a large series of patients with non-small cell lung carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, p53. Interleukin-8 / genetics. Lung Neoplasms / genetics. Neovascularization, Pathologic / genetics
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / blood supply. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Mutation. Polymerase Chain Reaction / methods. Prognosis. RNA, Messenger / analysis. RNA, Messenger / genetics. Survival Analysis. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125276.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / RNA, Messenger; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


12. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol; 2009 Apr 20;27(12):2030-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
  • PURPOSE: Recent advances in treatment of lung cancer require greater accuracy in the subclassification of non-small-cell lung cancer (NSCLC).
  • Targeted therapies which inhibit tumor angiogenesis pose higher risk for adverse response in cases of squamous cell carcinoma.
  • In this study, we set out to identify specific microRNA biomarkers for the identification of squamous cell carcinoma, and to use such markers for the development of a standardized assay.
  • PATIENTS AND METHODS: High-throughput microarray was used to measure microRNA expression levels in 122 adenocarcinoma and squamous NSCLC samples.
  • RESULTS: We identified hsa-miR-205 as a highly specific marker for squamous cell lung carcinoma.
  • A microRNA-based qRT-PCR assay that measures expression of hsa-miR-205 reached sensitivity of 96% and specificity of 90% in the identification of squamous cell lung carcinomas in an independent blinded validation set.
  • CONCLUSION: Hsa-miR-205 is a highly accurate marker for lung cancer of squamous histology.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Biological Assay. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction


13. Sawabata N, Miyoshi S, Matsumura A, Ohta M, Maeda H, Sueki H, Hayakawa M, Okumura M, Sawa Y: Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma. Gen Thorac Cardiovasc Surg; 2007 Oct;55(10):420-4
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma.
  • OBJECTIVE: Many patients who undergo surgery for non small-cell lung cancer (NSCLC) have a smoking habit, which is a risk factor for NSCLC and chronic obstructive pulmonary disease (COPD).
  • The never-smoked group had higher ratios for the factors female, pathological IA, adenocarcinoma, and favorable airway obstruction.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy. Pulmonary Disease, Chronic Obstructive / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018606.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


14. Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N: Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project. J Clin Oncol; 2009 May 20;27(15_suppl):1540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project.
  • : 1540 Background: We have investigated the individualized benefit of CT screening as Anti-Lung Cancer Association projects (presented at ASCO 2006-2008).
  • However, there has not been enough information about the relationship of lung cancer stage to tumor size in repeated CT screening.
  • Therefore, we evaluated the stage-size relationship of these asymptomatic lung cancer cases diagnosed by long-term repeated screening with low-dose helical CT.
  • Histology for the categories 15 mm or less was localized bronchioloalveolar carcinoma in 13 cases, adenocarcinoma with mixed subtype in 11 cases, invasive adenocarcinoma in five cases, other non-small cell carcinoma in 10 cases, and small cell carcinoma in one case.
  • CONCLUSIONS: These results provide direct evidence of a stage-size relationship in long-term repeated CT screening for lung cancer.
  • Furthermore, early detection of lung cancer of 15 mm or less in diameter leads to the detection of early-stage (N0M0) lung cancer in repeated CT screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Quesenberry PJ, Del Tatto M, Berz D, Miner T, Ng T, Winer ES, Aliotta J, Colvin G, Dooner M, Dooner G, Fontaine JP: Marrow cell genetic phenotype change induced by human lung cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):11108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow cell genetic phenotype change induced by human lung cancer cells.
  • : 11108 Background: Murine lung-derived microvesicles are capable of inducing lung-specific mRNA in marrow cells, when co-cultured across from these cells, but separated from them by a cell-impermeable (0.4 micron) membrane.
  • These converted murine marrow cells showed mRNA elevations, lung-specific protein production and enhanced capacity to convert to lung epithelial cells after in vivo transplantation into irradiated mice.
  • We examine here whether fresh tissue from lung cancer patients would have the same capacity to genetically alter co-cultured human marrow cells.
  • METHODS: Lung cancer samples were collected from 5 patients undergoing surgery.
  • Marrow cell RNA was analyzed for lung specific mRNA using real time RT-PCR.
  • RESULTS: Lung cancers studied were adenocarcinoma, endobronchial alveolar carcinoma, bronchioloalveolar carcinoma, non-small cell carcinoma and squamous cell carcinoma. mRNAs for aquaporin 1-5, specific for type I pneumocytes and surfactant A-D, specific for type II pneumocytes, were measured.
  • Aquaporin I was elevated in marrow cells from co culture with all lung cancers; elevations ranging from 2.15 to 56.7 fold (mean 23 fold).
  • Similarly surfactant B mRNA was induced in marrow cells by all lung cancers with fold elevations ranging from 7.9 to 2164 (mean fold elevation 668).
  • CONCLUSIONS: These observations indicate that the genetic phenotype of cells in the vicinity of lung cancer cells can be altered and that these alterations might be mediated by microvesicle transfer of genetic information.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Scagliotti G, Monica V, Ceppi P, Righi L, Cambieri A, Volante M, Novello S, Cappelletto E, Papotti M: Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer.
  • : 7521 Background: In non-small cell lung cancer (NSCLC) baseline thymidilate synthase (TS) levels are higher in squamous cell carcinoma (SCC) compared to adenocarcinoma (AC) and randomized clinical trials have shown a selective benefit for patients with non-squamous histology treated with pemetrexed, a TS-inhibiting agent.
  • TS expression in undifferentiated large cell carcinoma (LCC) is unknown.
  • c) in all histotypes TS protein level with desmocollin-3 (DSC-3) immunostaining, a marker of squamous cell differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963288.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study.
  • Baseline characteristics: median age 62 years (range 41-76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8.
  • In spite of the majority of patients are caucasian, males, smokers with squamous cell carcinoma, maintenance with single agent erlotinib reached a promising median OS of 18.7 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Novello S, Abrey LE, Grossi F, Camps C, Mazieres J, Selaru P, Patyna S, Torigoe Y, Chao R, Scagliotti G: Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial.
  • : 8077 Background: Sunitinib (SU), an oral, multitargeted inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and RET has promising single-agent antitumor activity in refractory non-small cell lung cancer (NSCLC) (Socinski JCO 2008).
  • Safety was assessed by monitoring adverse events (AEs) and health-related quality of life was assessed using FACT/NCCN Lung Symptom Index (FLSI) and Brain Symptom Index (FBrSI).
  • RESULTS: To date, 47 pts, including 28 with adenocarcinoma and 10 with squamous cell carcinoma, received SU for a median of 2 cycles (range: 1, 9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962653.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fan M, Xie L, Xu X, Zhang G, Chen J, Fu X, Zhou X, Li W, Jiang G: Phase I dose-escalation study of thoracic radiotherapy in combination with gefitinib in patients with IIIB/IV non-small cell lung cancer (NCT00497250). J Clin Oncol; 2009 May 20;27(15_suppl):e14581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of thoracic radiotherapy in combination with gefitinib in patients with IIIB/IV non-small cell lung cancer (NCT00497250).
  • However, a higher incidence of interstitial lung disease, sometimes lethal, is also found.
  • RESULTS: Since June 2007, 2 cohorts, a total of 16 patients, were enrolled and treated: 8 stage IIIB and 8 stage IV; 2 squamous-cell carcinoma and 14 adenocarcinoma; 8 smokers and 8 nonsmokers.
  • CONCLUSIONS: Thoracic radiotherapy up to 56 Gy concurrent with gefitinib 250 mg daily was well tolerated and clinically active in this group of pretreated Chinese NSCLC patients, including nonsmokers with adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963755.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sugarbaker DJ, Tilleman TR, Swanson SJ, Jaklitsch MT, Mentzer SJ, Mujoomdar AA, Bueno R: The role of extrapleural pneumonectomy in the management of pleural cancers. J Clin Oncol; 2009 May 20;27(15_suppl):7577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 32 patients had mediastinoscopy negative T4 lung cancer, 11 had metastases to only one pleura from extrathoracic sites, 10 had unilateral lung sarcomas involving the pleural envelope, 8 had thymomas metastatic to a pleural space, 2 were preoperatively diagnosed as mesotheliomas but at final pathology were determined to be small cell lung cancer and sarcomatoid carcinoma, and 2 represented primary mucoepidermoid and neuroectodermal malignancies.
  • Twenty-eight patients had stage IIIB (T4-N0-1) lung adenocarcinoma representing the largest homogeneous group of patients by cell type and stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, Watanabe N, Sakamoto J, Aoe M, Date H: A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses. J Clin Oncol; 2009 May 20;27(15_suppl):7560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses.
  • Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies.
  • The median survival time of A and B arms combined was 4.1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Luttgen MS, Marrinucci D, Lazar D, Malchiodi M, Clark P, Huynh E, Bethel K, Bazhenova L, Nieva J, Kuhn P: Circulating tumor cells monitored over time in lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):11025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells monitored over time in lung cancer patients.
  • : 11025 Background: Circulating tumor cell (CTC) detection and enumeration is a valuable tool for monitoring cancer patient status and outcome.
  • While many current techniques employ immunomagnetic-enrichment based protocols focused on the importance of a particular CTC number as the indicator of patient status or outcome, we employ a cytometric, enrichment free approach using an immunofluorescent protocol to monitor CTC counts in patients with non-small cell lung cancer (NSCLC) over the course of treatment.
  • The histological subtypes in the 42 cases for which the data was available included adenocarcinoma (22/42), squamous cell carcinoma (6/42), large cell undifferentiated carcinoma (3/42), and non-small cell lung carcinoma not further described, poorly differentiated, or with a mixed pattern (11/42).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963968.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ou SI, Zell JA: Frequency of carcinoma not otherwise specified (NOS) as a histologic diagnosis among non-small cell lung cancer (NSCLC) cases between 1989 to 2006: An epidemiologic study from the California Cancer Registry. J Clin Oncol; 2009 May 20;27(15_suppl):e19049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of carcinoma not otherwise specified (NOS) as a histologic diagnosis among non-small cell lung cancer (NSCLC) cases between 1989 to 2006: An epidemiologic study from the California Cancer Registry.
  • We investigated the distribution of carcinoma NOS (not otherwise specified) among NSCLC cases in California.
  • RESULTS: Carcinoma NOS accounted for 22.2% of all NSCLC patients, was most commonly diagnosed cytologically (36.7%) and had the worst 5-year survival estimates (5.8%) and median OS (5 months) compared to other major histologies.
  • The proportion of carcinoma NOS was highest among stage 4 disease and increased significantly from 1989 to 2006 among all patients, both males and females, all 4 major ethnicities (Caucasian, African-American, Hispanic, and Asian), all age- categories, and all AJCC stages.
  • The percentage of the very elderly (80+) increased from 10.8% to 17.1% among all NSCLC patients and they had the highest percentages of carcinoma NOS and cytologically-diagnosed NSCLC among all age categories.
  • Among stage 4 patients, carcinoma NOS patients derived less survival benefit from chemotherapy than adenocarcinoma patients during the most recent period of diagnosis and Cox proportional hazards analysis indicated carcinoma NOS (vs. adenocarcinoma; HR = 1.061, 95% CI: 1.040- 1.083) and cytologically-diagnosed NSCLC (vs. histologically-diagnosed NSCLC, HR = 1.043, 95% CI: 1.024-1.062) were independent unfavorable prognostic factors for OS.
  • CONCLUSIONS: Carcinoma NOS was a common histologic diagnosis and was increasing in proportion among NSCLC in California from 1989 to 2006.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962101.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg; 2005 Jan;102(s_supplement):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery.
  • OBJECT: The authors conducted a study to evaluate the long-term outcomes and prognostic factors for survival in a large series of patients treated by gamma knife surgery (GKS) for non-small cell lung cancer (NSCLC) brain metastases.
  • The most common histological types were adenocarcinoma (51%) and squamous cell carcinoma (27%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306429.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / non—small cell lung cancer
  •  go-up   go-down


27. Stoehlmacher J, Goekkurt E, Hoeffken G, Zinsky R, Lynch F, Buettner H, Scheil-Bertram S, Schirren J, Ehninger G, Fisseler-Eckhoff A: Thymidylate synthase polymorphisms and immunohistochemistry in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase polymorphisms and immunohistochemistry in non-small cell lung cancer.
  • : 11101 Background: Recently, pemetrexed has been introduced into the treatment of non-small cell lung cancer (NSCLC).
  • There's evidence that pemetrexed appears to be more efficient in non squamous NSCLC including adenocarcinoma (AC) and large cell carcinoma (LCC).
  • Distribution of histology was as follows: 50% AC, 42% squamous cell carcinoma (SCC), 3% LCC and 5% mixed or other histological subtypes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology; 2007 Mar;242(3):882-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.
  • PURPOSE: To retrospectively assess possible clinical predictors of metastatic disease to the brain in patients with non-small cell lung carcinoma (NSCLC).
  • Hierarchical logistic regression was used to determine the predicted probability of metastatic disease to the brain as a function of patient age and sex and of size, cell type, peripheral versus central location, and lymph node stage of the primary NSCLC.
  • Cell types included adenocarcinoma (136 [52%] patients), undifferentiated (68 [26%] patients), and squamous (47 [18%] patients), for which metastatic disease to the brain occurred in 43%, 41%, and 13% (P = .003) of patients, respectively.
  • The predicted probability of metastatic disease to the brain correlated positively with size of the primary tumor (P < .001), cell type (adenocarcinoma and undifferentiated vs squamous, P = .001), and lymph node stage (P < .017) but did not correlate with age, sex, or primary tumor location.
  • For primary adenocarcinoma without lymph node spread, the predicted probabilities of metastatic disease to the brain from 2- and 6-cm primary tumors were .14 (95% confidence interval: .06, .27) and .72 (95% confidence interval: .48, .88), respectively (P < .02).
  • CONCLUSION: The probability of metastatic disease to the brain from primary NSCLC is correlated with size of the primary tumor, cell type, and intrathoracic lymph node stage.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / epidemiology. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229875.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Sorensen J, Hansen O, Vilmar A, Frank H: Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer.
  • Overall, median age was 62 years (range 38-75 yrs), 58% were males, 11% had performance status 2, 62% stage IV disease, 46% adenocarcinoma, and 28% squamous cell carcinoma (SCC), equally distributed between the regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962834.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Chen QY, Jiang ZY, Wu LJ, Zhang BY, Lu GH, Zhou JY: [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):278-82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma].
  • OBJECTIVE: To detect the expression of alpha-tubulin and MDR1 in human non-small cell lung carcinoma (NSCLC), and to clarify their clinical significance.
  • METHODS: Paraffin embedded tissues from 158 primary non-small lung carcinomas and 30 paracancerous lung tissues were examined for expression of alpha-tubulin and MDR1 by immunohistochemistry (SP method).
  • The relationship between alpha-tubulin and MDR1 expression and the biological features of lung carcinoma was analyzed.
  • RESULTS: The positive rate of alpha-tubulin and MDR1 expressions in the lung carcinomas was 65.2% and 51.3%, respectively.
  • There was no expression of either of them in 30 paracancerous lung tissues.
  • But the positive rate of MDR1 in adenocarcinoma was significantly higher than that in squamous carcinoma and undifferentiated large cell carcinomas (P < 0.01).
  • Univariate analysis showed that the 5-year survival rate of patients with negative alpha-tubulin and MDR1 expression was 30.7% and 28.5%, respectively, significantly higher than that of patients with positive alpha-tubulin and MDR1 expression (13.5% and 11.8%, respectively) (chi(2) = 20.69 and 15.52, P < 0.01, respectively), and multivariate Cox regression analysis showed that alpha-tubulin (RR = 3.287, P = 0.006) and clinical TNM stage (RR = 1.954, P = 0.025) were significantly independent predictive factor for patients with lung cancer, MDR1 and other factors could not be used as an independent predicitive factors.
  • However, there was no significant correlation between the expression of alpha-tubulin and MDR1 in lung carcinoma(r = 0.093, P > 0.05).
  • CONCLUSION: The expression of alpha-tubulin and MDR1 may play an important role in the development and progression of human non-small cell lung carcinoma.
  • Combined detection could be considered as an important index for predicting prognosis of lung carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. P-Glycoprotein / metabolism. Tubulin / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. P-Glycoproteins. Paraffin Embedding. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Proportional Hazards Models. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510079.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / TUBA1A protein, human; 0 / Tubulin
  •  go-up   go-down


31. Lee MK, Kim JH, Lee CH, Kim JM, Kang CD, Kim YD, Choi KU, Kim HW, Kim JY, Park DY, Sol MY: Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival. Pathology; 2006 Dec;38(6):555-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival.
  • This study was performed to investigate BGP expression in non-small-cell lung carcinoma (NSCLC).
  • METHODS: A total of 119 cases of NSCLC, including 63 squamous cell carcinomas (SqCCs) and 56 adenocarcinomas (ACs), were imunohistochemically evaluated for BGP expression, and its expression was correlated with clinicopathological parameters.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / pathology. Glycogen Phosphorylase, Brain Form / metabolism. Lung Neoplasms / blood supply. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Lung / blood supply. Lung / metabolism. Lung / pathology. Male. Microcirculation. Middle Aged. Prognosis. Sex Characteristics. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393985.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.4.1.- / Glycogen Phosphorylase, Brain Form
  •  go-up   go-down


32. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol; 2006 Jun;125(6):860-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
  • We evaluated epidermal growth factor receptor (EGFR) protein expression by immunohistochemical analysis and EGFR gene amplification by fluorescence in situ hybridization in 199 consecutive newly diagnosed and surgically treated patients with primary non-small cell lung carcinoma (NSCLC) and correlated results with clinicopathologic findings.
  • EGFR protein expression was more common in squamous cell carcinoma (SCC; 17 [26.2%]) than in adenocarcinoma (14 [11.1%]; (P = .0076) and more frequently associated with EGFR amplification (8 [14.5%] vs 4 [3.6%] cases; P = .0208).
  • Poor differentiation was associated with a higher average number of EGFR gene copies per cell (mean, 4.18; P = .0322) and a higher EGFR/chromosome 7 ratio (mean, 1.84; P = .0324).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Gene Amplification. Lung Neoplasms / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Chromosomes, Human, Pair 7. Disease-Free Survival. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Staging. Prospective Studies


33. Takahashi T, Yamamoto N, Murakami H, Ohe Y, Kunitoh H, Nokihara H, Koshiji M, Tamura T: A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):2572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC).
  • Pre-clinical data shows Enz's synergistic activity with Pem in many cancer cell lines including NSCLC.
  • This phase 1 study is to evaluate the safety, pharmacokinetics (PK), and clinical activity of two schedules of Enz combined with Pem in patients (pts) with previously treated advanced NSCLC.
  • RESULTS: 12 pts (8 males, 4 females; ECOG PS 0-1) with median age of 62 (49 - 74) were enrolled into this study and completed safety evaluation for cycle 1: 8 pts with adenocarcinoma, 3 pts with squamous cell carcinoma, and one with other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Grilley-Olson JE, Hayes DN, Qaqish BF, Moore DT, Socinski MA, Yin X, Wilkerson MD, Leslie KO, Travis WD, Funkhouser WK Jr, VOILA Group: Validation of Inter-Observer Agreement in Lung Cancer Assessment: Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):8008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study.
  • METHODS: Pathologists (P) assigned WHOC diagnoses to virtual H&E slides from an incident surgical cohort of 96 primary lung tumors.
  • RESULTS: 12 self-identified "lung experts" (E) and 12 community (C) P scored slides based on the 44 possible WHOC DC totaling 222 pathologist-pairs and 7130 slides-pairs.
  • Distribution of DC included SC 30% and adenocarcinoma 36%.
  • Although this model tests the reproducibility of the WHOC, not clinical lung cancer diagnoses, it shows that reproducible diagnosis of SC based on H&E morphology alone is inadequate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Dooms C, Verbeken E, Stroobants S, Vansteenkiste J: Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy. J Thorac Oncol; 2009 Oct;4(10):1221-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy.
  • We aimed to investigate the mechanisms that drive persistent FDG uptake in non-small cell lung carcinoma treated with IC.
  • Immunohistochemical staining was assessed for microvessel density, markers of cell proliferation (Ki-67), hypoxia (HIF-1alpha), extracellular acidification (CAIX), and p-Akt.
  • Although surrogate markers for tumor hypoxia and acidity showed a trend for correlation with increased glycolysis in pretreated stage IIIA-N2 non-small cell lung carcinoma, these markers did not contribute to the recognition of metabolic responders versus nonresponders.
  • We observed that only surrogate markers of cell proliferation correlate with a metabolic response after IC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radionuclide imaging. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19641474.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Tanaka J, Tajima S, Ito R, Shimaoka Y, Kuriyama H, Kagamu H, Terada M, Takada T, Gejyo F, Suzuki E, Yoshizawa H, Narita I: [A case of non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis]. Nihon Kokyuki Gakkai Zasshi; 2009 Jul;47(7):652-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis].
  • At the time of admission the chest X-ray film showed infiltrative shadows in the left middle and lower lung fields.
  • Our investigation revealed primary mucinous type bronchioloalveolar carcinoma in the left lung (cT4N2M1 Stage IV).
  • However the ground-glass appearance appeared in the right lung a few days later.
  • Necropsy findings revealed bronchioloalveolar carcinoma in the right lung suggesting aerogenous metastasis.
  • Considering these facts together, we diagnosed non-small cell lung carcinoma dying of acute respiratory failure due to aerogenous metastasis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637811.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol; 2006 May;28(5):1089-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
  • To evaluate the potential of two members of this family, MAGE-A4 and NY-ESO-1 antigens, for cancer vaccine in non-small cell lung carcinoma (NSCLC), we examined the expression of these antigens and T cell infiltration in tumor tissue, and evaluated their prognostic significance.
  • Immunohistochemistry was performed for NY-ESO-1 expression and T cell infiltration into the tumor site.
  • Both CT antigens were more frequently expressed in squamous cell carcinoma (SCC) than in adenocarcinoma.
  • Combined infiltration of both CD4+ and CD8+ T cells into tumor nest predicted better survival.
  • MAGE-A4 expression in advanced group and T cell infiltration may provide prognostic information.
  • [MeSH-major] Antigens, Neoplasm / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Neoplasm Proteins / genetics. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596224.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Cancer Vaccines; 0 / DNA Primers; 0 / MAGEA4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


38. Tagawa T, Osoegawa A, Yamazaki K, Okamoto T, Kometani T, Wataya H, Seto T, Fukuyama S, Hirai F, Sugio K, Ichinose Y: Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution. J Surg Oncol; 2010 May 1;101(6):495-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution.
  • OBJECTIVES: We evaluated the efficacy of the multimodality approach in treating superior sulcus non-small cell lung carcinoma (SS NSCLC).
  • Methods of clinical staging were unchanged between the two time periods, although the ratio of adenocarcinoma was increased, and multimodality treatment, particularly concurrent chemoradiotherapy followed by surgical resection, was used more frequently in the second half of the study period.
  • [MeSH-major] Lung Neoplasms / therapy. Small Cell Lung Carcinoma / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20191604.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J: No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer; 2005 Aug;49(2):155-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
  • Moreover, they play roles in regulation of cell growth, apoptosis, angiogenesis and immune surveillance.
  • The aim of this study is to assess the effects of the C-1562T polymorphism in the MMP-9 promoter on the risk of occurrence and lymphatic metastasis of non-small cell lung carcinoma (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Lymphatic Metastasis / genetics. Matrix Metalloproteinase 9 / genetics. Polymorphism, Single Nucleotide / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / enzymology. Neoplasm Recurrence, Local / genetics. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949868.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


40. Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, Simao L, Wands JR, Resnick MB, Wang L: Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol; 2009 May;40(5):639-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma.
  • Despite improvements in the detection and use of biomarkers, including epidermal growth factor receptor, ERCC1, and p16, the 5-year survival rate with non-small cell lung cancer remains at 15%.
  • We now characterize the prognostic use of aspartyl (asparaginyl)-beta-hydroxylase/humbug immunoreactivity in different subtypes of non-small cell lung cancer.
  • Tissue microarrays including 375 paraffin-embedded non-small cell lung cancers (195 adenocarcinomas; 18 bronchioloalveolar carcinomas; 113 squamous cell carcinomas; and 49 large cell carcinomas) were immunostained with FB50 monoclonal antibody, which recognizes human aspartyl (asparaginyl)-beta-hydroxylase/humbug.
  • High levels of FB50 immunoreactivity were more often detected in adenocarcinomas (28% for adenocarcinoma, 17% for bronchioloalveolar carcinoma), compared with squamous cell carcinomas (10%) and large cell carcinomas (10%).
  • Univariate analysis demonstrated inverse relationships between intensity of FB50 immunoreactivity and survival with squamous cell carcinoma (P = .004), and a strong trend with respect to large cell carcinoma (P = .057).
  • Cox multivariate test showed that FB50 immunoreactivity (P = .025), clinical stage (P = .029), and tumor size (P = .0001) were all independent predictors of survival with squamous cell carcinoma.
  • High levels of FB50 immunohistochemical staining correlate with poor prognosis in non-small cell lung cancer, particularly squamous cell carcinoma subtype.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2002 Aug;302(2):795-803 [12130746.001]
  • [Cites] Pancreas. 2002 Jul;25(1):39-44 [12131769.001]
  • [Cites] J Hepatol. 2003 May;38(5):615-22 [12713872.001]
  • [Cites] Genes Dev. 2004 Jan 1;18(1):99-115 [14701881.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • [Cites] J Cell Biol. 2004 Aug 16;166(4):537-48 [15302852.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(10):3609-13 [2726737.001]
  • [Cites] J Biol Chem. 1990 May 25;265(15):8558-65 [2187868.001]
  • [Cites] J Biol Chem. 1990 Oct 25;265(30):18481-9 [2145284.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7227-31 [8041771.001]
  • [Cites] Gene. 1994 Dec 15;150(2):395-9 [7821814.001]
  • [Cites] J Clin Invest. 1996 Sep 15;98(6):1313-23 [8823296.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Viral Hepat. 1997;4 Suppl 2:60-74 [9429211.001]
  • [Cites] Cancer Detect Prev. 2004;28(5):313-8 [15542253.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3974-86 [15930332.001]
  • [Cites] J Hepatol. 2006 May;44(5):971-83 [16564107.001]
  • [Cites] Hepatology. 2006 Aug;44(2):446-57 [16871543.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):17-25 [17020779.001]
  • [Cites] BMC Cell Biol. 2006;7:41 [17156427.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1091:184-90 [17341613.001]
  • [Cites] J Thorac Oncol. 2007 Jun;2 Suppl 2:S68-76 [17589302.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 12;362(1):1-4 [17706594.001]
  • [Cites] Stem Cell Rev. 2007 Jan;3(1):7-17 [17873377.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):795-800 [18288418.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1261-6 [10728685.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39543-54 [10956665.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39555-68 [11007777.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):277-83 [11181774.001]
  • [Cites] Thorax. 2001 Jul;56(7):561-6 [11413356.001]
  • [Cites] Lab Invest. 2002 Jul;82(7):881-91 [12118090.001]
  • (PMID = 19200576.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA011431-12A1; United States / NIAAA NIH HHS / AA / AA012908-04; United States / NIAAA NIH HHS / AA / R37 AA011431; United States / NIAAA NIH HHS / AA / AA016126-05; United States / NIAAA NIH HHS / AA / AA011431-12; United States / NIAAA NIH HHS / AA / K24 AA016126-04; United States / NCRR NIH HHS / RR / P20 RR024484-01; United States / NIAAA NIH HHS / AA / R01 AA012908-04; United States / NIAAA NIH HHS / AA / R01 AA012908-03; United States / NIAAA NIH HHS / AA / AA016126-04; United States / NIAAA NIH HHS / AA / R01 AA012908; United States / NIAAA NIH HHS / AA / R56 AA011431-12; United States / NIAAA NIH HHS / AA / R56 AA011431; United States / NIGMS NIH HHS / GM / P20 GM104937; United States / NIAAA NIH HHS / AA / R01 AA012908-08; United States / NCRR NIH HHS / RR / P20 RR024484; United States / NIAAA NIH HHS / AA / AA012908-08; United States / NIAAA NIH HHS / AA / K24 AA016126; United States / NIAAA NIH HHS / AA / R37 AA011431-12A1; United States / NIAAA NIH HHS / AA / AA012908-03; United States / NCRR NIH HHS / RR / RR024484-01; United States / NIAAA NIH HHS / AA / K24 AA016126-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 1.- / Mixed Function Oxygenases; EC 1.14.11.- / aspartic acid 2-oxoglutarate-dependent dioxygenase
  • [Other-IDs] NLM/ NIHMS208790; NLM/ PMC2893029
  •  go-up   go-down


41. Miki Y, Suzuki T, Abe K, Suzuki S, Niikawa H, Iida S, Hata S, Akahira J, Mori K, Evans DB, Kondo T, Yamada-Okabe H, Sasano H: Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res; 2010 Aug 15;70(16):6659-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
  • Estrogens produced as a result of intratumoral aromatization has been recently shown to play important roles in proliferation of human non-small cell lung carcinomas (NSCLC), but the details have remained largely unknown.
  • Therefore, in this study, we evaluated the possible roles of intratumoral aromatase in NSCLCs as follows: (a) evaluation of intratumoral localization of aromatase mRNA/protein in six lung adenocarcinoma cases using laser capture microdissection combined with quantitative reverse transcriptase-PCR and immunohistochemistry;.
  • (b) examination of the possible effects of isolated stromal cells from lung carcinoma tissues on aromatase mRNA transcript expression in lung carcinoma cell lines (A549 and LK87) through a coculture system; and (c) screening of cytokines derived from stromal LK001S and LK002S cells using cytokine antibody arrays and subsequent evaluation of effects of these cytokines on aromatase expression in A549 and LK87.
  • Both aromatase mRNA and protein were mainly detected in intratumoral carcinoma cells but not in stromal cells.
  • These results all indicated that intratumoral microenvironments, especially carcinoma-stromal cell interactions, play a pivotal role in the regulation of intratumoral estrogen synthesis through aromatase expression in human lung adenocarcinomas.
  • [MeSH-major] Aromatase / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Cell Communication / physiology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Androgens / biosynthesis. Cell Line, Tumor. Coculture Techniques. Estradiol / analogs & derivatives. Estradiol / pharmacology. Estrogens / biosynthesis. Female. Humans. Immunohistochemistry. Interleukin-6 / biosynthesis. Male. Middle Aged. Oncostatin M / biosynthesis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / enzymology. Stromal Cells / pathology. Tumor Necrosis Factor-alpha / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • (PMID = 20710045.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / Interleukin-6; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 106956-32-5 / Oncostatin M; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


42. Wong ET, Wu JK, Mahadevan A: Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma. Biologics; 2007 Sep;1(3):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma.
  • We report a patient with rapid neurologic deterioration from carcinomatous encephalitis from lung adenocarcinoma.
  • Gefitinib and high-dose fractionated radiotherapy may have synergistic activity in patients with carcinomatous encephalitis from non-small cell lung cancer having favorable prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3250-8 [12374696.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4517-20 [16983123.001]
  • [Cites] Neurology. 2005 Jul 12;65(1):165 [16009912.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2026-33 [15545965.001]
  • [Cites] Neuroradiology. 1997 Jun;39(6):437-40 [9225326.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14(3):540-2 [8517338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Dec;7(12):1633-8 [6174490.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9 [6154024.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] Br J Cancer. 2003 Dec;89 Suppl 2:S15-8 [14661048.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 19707341.001).
  • [ISSN] 1177-5475
  • [Journal-full-title] Biologics : targets & therapy
  • [ISO-abbreviation] Biologics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2721320
  • [Keywords] NOTNLM ; Gefitinib / brain metastases / radiation
  •  go-up   go-down


43. Zolota VG, Tzelepi VN, Leotsinidis M, Zili PE, Panagopoulos ND, Dougenis D, Tsamandas AC, Scopa CD: Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma. J Surg Res; 2010 Dec;164(2):256-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma.
  • BACKGROUND: Lung cancer is the most lethal type of cancer in humans.
  • Cell cycle alterations have commonly been encountered in lung cancer and may have prognostic value.
  • MATERIALS AND METHODS: This study investigates the immunohistochemical expression of the important cell cycle regulators phosphatase and tensin homolog deleted on chromosome 10 (PTEN), p27, Cks1, and Skp2 in 128 non-small cell lung carcinomas (64 adenocarcinomas, 46 squamous cell carcinomas, and 18 large cell undifferentiated carcinomas) and adjacent non-neoplastic lung tissue.
  • RESULTS: PTEN and p27 were always highly expressed in non-neoplastic lung whereas Cks1 and Skp2 were not expressed in normal tissue.
  • Decreased PTEN expression was noted in 19/64 adenocarcinomas, 15/46 squamous cell carcinomas, and 7/18 undifferentiated large cell carcinomas.
  • An inverse relationship between p27 and Skp2 levels was found in adenocarcinomas and between p27 and Cks1 levels in squamous cell carcinomas.
  • Decreased PTEN and p27 expression were associated with advanced tumor stage in squamous cell carcinomas.
  • Univariate analysis showed that high p27 and PTEN and low Cks1 expression correlated with increased survival in patients with squamous cell carcinoma independently of tumor stage.
  • CONCLUSIONS: Aberrant expression of PTEN, p27, Cks1, and Skp2 is a common feature of all three major types of non-small cell lung cancer NSCLC, but seems to be involved in the progression of squamous cell carcinoma alone.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / surgery. CDC2-CDC28 Kinases. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carrier Proteins / genetics. Cell Cycle. Cyclin-Dependent Kinases / genetics. Humans. Immunohistochemistry. Neoplasm Staging. PTEN Phosphohydrolase / genetics. Proliferating Cell Nuclear Antigen / genetics. S-Phase Kinase-Associated Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19691991.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKS1B protein, human; 0 / Carrier Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / S-Phase Kinase-Associated Proteins; 0 / p27 antigen; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


44. Sánchez-Ceja SG, Reyes-Maldonado E, Vázquez-Manríquez ME, López-Luna JJ, Belmont A, Gutiérrez-Castellanos S: Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer; 2006 Nov;54(2):163-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma.
  • Experimental evidence suggests that in lung cancer, development, progression and an increased proliferation rate can be linked to apoptosis-related factors.
  • The objective of this study is to evaluate the status of Neu, signal transducer and activator of transcription (STAT)-3, STAT5 and Bcl-xL expression in non-small-cell lung cancer.
  • We investigated the immunohistochemical expression of these proteins in 92 non-small-cell lung cancer specimens to establish their role in lung cancer pathogenesis.
  • Finally, we found correlation among histological types of lung cancer and nuclear expression of both STAT5 (P=0.005) and nuclear Bcl-xL (P=0.003).
  • These results suggest for the first time, a relevant role for STAT5 and Bcl-xL as apoptosis-regulatory proteins in the pathogenesis of lung cancer, and overexpression of both Neu and activated STAT3, could be related with the proliferation rate in lung carcinoma cells.
  • [MeSH-major] Lung Neoplasms / metabolism. Receptor, ErbB-2 / metabolism. STAT3 Transcription Factor / metabolism. STAT5 Transcription Factor / metabolism. bcl-X Protein / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Apoptosis. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Proliferation. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959370.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 0 / bcl-X Protein; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


45. Khan ZA, Caurtero J, Barbin YP, Chan BM, Uniyal S, Chakrabarti S: ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res; 2005 Sep;31(7):701-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ED-B fibronectin in non-small cell lung carcinoma.
  • The present study was aimed at elucidating whether ED-B FN is expressed in non-small cell lung carcinomas and whether such aberrant expression correlates with tumoral angiogenesis.
  • Frozen tissues from 28 non-small cell lung carcinomas (consisting of both squamous cell carcinomas and adenocarcinomas) along with paired normal tissue samples were collected from the tissue bank collection of the Department of Pathology, London Health Sciences Center, Canada.
  • The results demonstrate up-regulation of ED-B FN mRNA levels in lung tumor tissues as compared to paired normal tissues.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Fibronectins / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adult. Alternative Splicing. Base Sequence. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Gene Expression. Humans. Neovascularization, Pathologic. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203624.001).
  • [ISSN] 0190-2148
  • [Journal-full-title] Experimental lung research
  • [ISO-abbreviation] Exp. Lung Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FN1 protein, human; 0 / Fibronectins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


46. Yoon MY, Song CS, Seo MH, Kim MJ, Oh TY, Jang UH, Kwag HJ, Kim HS, Lim SY, Lim SY, Lee SS: A case of metachronous metastasis to the breast from non-small cell lung carcinoma. Cancer Res Treat; 2010 Sep;42(3):172-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metachronous metastasis to the breast from non-small cell lung carcinoma.
  • We report here on a case of a 42-year-old female with metastasis of non-small cell lung cancer to the breast, and she is now being followed up on an outpatient basis.
  • In 2004, she presented with a solitary pulmonary nodule in the left lung, and this lesion had been noted to have gradually increased in size over time.
  • The final pathological diagnosis was adenocarcinoma, and the diagnosis was made by performing percutaneous needle aspiration and lobectomy of the left upper lobe.
  • Unfortunately, a nodule in the left breast was noted three years later, and metastatic non-small-cell lung cancer to the breast was diagnosed by excisional biopsy.
  • Making the correct diagnosis to distinguish a primary breast carcinoma from a metastatic one is important, because the therapeutic plan and outcome for these two types of cancer are quite different.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948923.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2953781
  • [Keywords] NOTNLM ; Adenocarcinoma / Metachronous breast metastasis / Non-small cell lung carcinoma
  •  go-up   go-down


47. Radović S, Babić M, Dorić M, Hukić A, Kuskunović S, Hadzismajlović A, Serdarević F: Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors. Bosn J Basic Med Sci; 2007 Aug;7(3):205-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.
  • The aim of this study was to investigate expression of cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins in 14 cases of non-small cell lung cancer and to establish their correlation to classical clinico-pathological findings, and alleged prognostic value to estimate biological potential of tumor.
  • Retrospective pilot study of the surgically treated non-small cell lung cancer biopsy specimen, paraffin embedded, used immunohistochemical method to demonstrate expression of cyclin D1, bcl-2, p53, Ki-67 and HER-2.
  • Out of 14 cases of non-small cell lung cancer, squamous cell carcinoma was found in 7 patients, giant cell carcinoma in 3, adenocarcinoma in 2, and 1 case of pleomorphic and mucoepidermoid carcinoma.
  • Since the proliferative activity of the tumor, measured by the expression of Ki-67, is correlated to the gradus and size of the tumor mass, Ki-67 protein can be of a prognostic value to determine biological potential of non-small cell lung cancer.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848143.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


48. Hastings RH, Montgrain PR, Quintana R, Rascon Y, Deftos LJ, Healy E: Cell cycle actions of parathyroid hormone-related protein in non-small cell lung carcinoma. Am J Physiol Lung Cell Mol Physiol; 2009 Oct;297(4):L578-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle actions of parathyroid hormone-related protein in non-small cell lung carcinoma.
  • Parathyroid hormone-related protein (PTHrP), a paraneoplastic protein expressed by two-thirds of human non-small cell lung cancers, has been reported to slow progression of lung carcinomas in mouse models and to lengthen survival of patients with lung cancer.
  • This study investigated the effects of ectopic expression of PTHrP on proliferation and cell cycle progression of two human lung adenocarcinoma cell lines that are normally PTHrP negative.
  • Stable transfection with PTHrP decreased H1944 cell DNA synthesis, measured by thymidine incorporation, bromodeoxyuridine uptake, and MTT proliferation assay.
  • In summary, PTHrP appears to slow progression of lung cancer cells into S phase, possibly by decreasing activation of CDK2.
  • Slower cancer cell proliferation could contribute to slower tumor progression and increased survival of patients with PTHrP-positive lung cancer.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):L941-9 [9374720.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1313-20 [17676588.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jul;279(1):E60-7 [10893323.001]
  • [Cites] Immunol Cell Biol. 2000 Aug;78(4):395-402 [10947864.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):694-703 [11159841.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):234-7 [11158193.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2282-8 [11280799.001]
  • [Cites] J Endocrinol. 2001 Aug;170(2):433-40 [11479139.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1402-10 [11745216.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Dec;285(6):C1429-36 [12917104.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Dec;285(6):L1312-22 [12922983.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9233-47 [14670956.001]
  • [Cites] Circulation. 2004 Jul 13;110(2):177-85 [15210588.001]
  • [Cites] Science. 1987 Dec 11;238(4833):1568-70 [3685995.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2732-6 [1313566.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):850-3 [8306349.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] Endocr Rev. 1994 Feb;15(1):40-60 [8156938.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4064-75 [7623802.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] Endocrinology. 1996 May;137(5):1608-17 [8612492.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13630-5 [9391077.001]
  • [Cites] Annu Rev Biochem. 1998;67:265-306 [9759490.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1028-34 [10491530.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2622-8 [15517575.001]
  • [Cites] Regul Pept. 2005 Feb 15;125(1-3):17-27 [15582709.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):311-21 [15840440.001]
  • [Cites] J Bone Miner Res. 2005 Jun;20(6):1051-64 [15883646.001]
  • [Cites] Cell Cycle. 2006 Jan;5(1):61-70 [16294008.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):990-8 [16293661.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):499-506 [16428492.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2250-6 [16489028.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):6015-22 [10606251.001]
  • (PMID = 19633068.001).
  • [ISSN] 1522-1504
  • [Journal-full-title] American journal of physiology. Lung cellular and molecular physiology
  • [ISO-abbreviation] Am. J. Physiol. Lung Cell Mol. Physiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023100; United States / NCI NIH HHS / CA / CA23100
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; 0 / Receptor, Parathyroid Hormone, Type 1; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  • [Other-IDs] NLM/ PMC2770787
  •  go-up   go-down


49. Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H, Rubin MA: TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol; 2009 Jan;217(1):65-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.
  • Such genetic alterations occur in a significant proportion of non-small cell lung carcinomas (NSCLCs) and include amplification of 14q13.3, which contains the TTF1 gene.
  • We found TTF1 amplification in approximately 13% of adenocarcinomas (ACs) and in approximately 9% of squamous cell carcinomas (SCCs) and TTF1 amplification was associated with increased TTF1 protein expression.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18932182.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  •  go-up   go-down


50. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res; 2010 Jan 15;16(2):610-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach.
  • PURPOSE: Advances in targeted lung cancer therapy now demand accurate classification of non-small cell lung cancer (NSCLC).
  • For example, hsa-miR-205 is a miRNA that is highly expressed in lung squamous cell carcinomas (SqCC) but not in lung adenocarcinomas.
  • EXPERIMENTAL DESIGN: One hundred and two resected NSCLCs were classified as SqCC or adenocarcinoma based on their histologic features and immunohistochemical profiles.
  • A quantitative reverse transcription-PCR diagnostic assay that measures the expression level of hsa-miR-205 was used to classify the carcinomas as SqCC or adenocarcinoma based solely on expression levels.
  • RESULTS: Using standard pathologic methods of classification (i.e., microscopy and immunohistochemistry), 52 resected lung carcinomas were classified as SqCCs and 50 as adenocarcinomas.
  • Indeed, classification is consistently accurate even in small biopsies/aspirates of poorly differentiated tumors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / classification. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / classification. Lung Neoplasms / genetics. MicroRNAs / analysis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Neoplasm Staging / methods. Nuclear Proteins / metabolism. Sensitivity and Specificity. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068099.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


51. Ythier D, Brambilla E, Binet R, Nissou D, Vesin A, de Fraipont F, Moro-Sibilot D, Lantuejoul S, Brambilla C, Gazzeri S, Pedeux R: Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. Lung Cancer; 2010 Aug;69(2):180-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma.
  • ING2 is a candidate tumor suppressor gene involved in cell cycle control, apoptosis and senescence.
  • We investigated its status in a series of 120 non-small cell lung cancer (NSCLC) by using immunohistochemistry (IHC).
  • The results showed that ING2 protein expression is downregulated in more than 50% of NSCLC, with a higher frequency in adenocarcinoma (ADK) as compared to squamous cell carcinoma (SCC) (68% versus 45%, P=0.021).
  • Overall, these results indicate that loss of ING2 expression could contribute to lung tumorigenesis independently of p53.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Homeodomain Proteins / biosynthesis. Lung Neoplasms / genetics. Receptors, Cytoplasmic and Nuclear / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19962781.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / ING2 protein, human; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


52. Kocak M, Mayadagli A, Ozkan A, Parlak C, Demir O, Marti A, Dogan Eren M, Kaya S, Gumus M: Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience. J BUON; 2007 Oct-Dec;12(4):471-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
  • PURPOSE: Despite advances in the detection and treatment, the long-term survival of patients with advanced nonsmall cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%.
  • Histological type was squamous cell carcinoma in 21 (42%) patients, adenocarcinoma in 11 (22%) and undifferentiated carcinoma in 18 (36%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067204.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Ozbudak IH, Ozbilim G, Kucukosmanoglu I, Dertsiz L, Demircan A: Vascular endothelial growth factor expression and neovascularization in non--small cell lung carcinoma. Int J Surg Pathol; 2009 Oct;17(5):390-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor expression and neovascularization in non--small cell lung carcinoma.
  • The prognostic significance of microvascular density (MVD) and vascular endothelial growth factor (VEGF) expression were investigated in 15 patients with adenocarcinoma (AC) and 15 patients with squamous cell carcinoma (SCC).
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung / blood supply. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849317.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9001-27-8 / Factor VIII
  •  go-up   go-down


54. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis; 2005 Feb;26(2):293-301
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma.
  • Here we show that RAGE is strongly reduced at the mRNA and even more so at the protein level in non-small cell lung carcinomas compared with normal lung tissues.
  • Down-regulation of RAGE correlates with higher tumour (TNM) stages but does not depend on the histological subtypes, squamous cell lung carcinoma and adenocarcinoma.
  • Subsequent overexpression of full-length human RAGE in lung cancer cells (NCI-H358) showed diminished tumour growth under some conditions.
  • Thus, down-regulation of RAGE may be considered as a critical step in tissue reorganization and the formation of lung tumours.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Cell Proliferation. Down-Regulation / physiology. Lung Neoplasms / metabolism. Receptors, Immunologic / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15539404.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Receptors, Immunologic; 9007-34-5 / Collagen
  •  go-up   go-down


55. Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH: Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. Lung Cancer; 2008 Dec;62(3):334-43
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
  • BACKGROUND: Epirubicin was effective for the treatment of non-small cell lung carcinoma (NSCLC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Antigens, Neoplasm / metabolism. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Endonucleases / metabolism. Epirubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18450322.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Laskin JJ, Pugh T, Jackson C, Sutcliffe M, Ionescu D, Melosky B, Ho C, Sun S, Murray N, Marra M: Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome-wide mutation discovery in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer.
  • Eligibility criteria included: stage IIIB/IV NSCLC; no prior chemo; ECOG ≤2; at least 2 of the following 4 criteria: women, never-smokers, Southeast Asian origin, adenocarcinoma and/or BAC.
  • Pathology: 44 ACA; 3 BAC;1 squamous carcinoma; 13 NSCLC NOS.
  • The discovery of novel mutations in multiple pts suggests patterns that may shed light on lung cancer specific behaviour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • Preclinical studies revealed that activated NK cells massively infiltrate lung tissue and improve recipient survival, suggesting a potential role in lung cancer therapeutics.
  • Pts characteristics: M/F 12/4; histology: adenocarcinoma/squamous cell carcinoma 13/3; stage IIIb/IV 2/14; 1<sup>st</sup>/2<sup>nd</sup> line treatment 13/3; median age 64 years (range, 50-71).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G: Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther; 2006 Nov;5(11):2905-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
  • We assessed aurora B expression in a series of 160 non-small cell lung cancer (NSCLC) samples (60% stage I, 21% stage II, 11% stage III, and 8% stage IV).
  • In addition, we determined the expression of survivin and p16, two molecules also involved in cell cycle control.
  • High aurora B expression levels were significantly associated with older age (P = 0.012), male sex (P = 0.013), squamous cell carcinoma histology (P = 0.001), poor tumor differentiation grade (P = 0.007), and lymph node invasion (P = 0.037), in the subset of radically resected patients in our series.
  • In addition, aurora B expression predicted shorter survival for the patients with adenocarcinoma histology, at both univariate (P = 0.020) and multivariate (P = 0.012) analysis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Protein-Serine-Threonine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121938.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline; 0 / BIRC5 protein, human; 0 / Benzamides; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Enzyme Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Quinazolines; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


59. Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, Yang YP, Wu CY, Shih FY, Liu CC, Lin HP, Jou YS, Lin SC, Lin CW, Chen WJ, Chan WK, Chen JJ, Yang PC: A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst; 2006 Jun 21;98(12):825-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
  • Here, we investigated the clinical significance of HLJ1 expression in non-small-cell lung cancer (NSCLC) patients and its role in cancer progression.
  • METHODS: We induced HLJ1 overexpression or knockdown in human lung adenocarcinoma CL1-5 cells and analyzed cell proliferation, anchorage-independent growth, in vivo tumorigenesis, cell motility, invasion, and cell cycle progression.
  • RESULTS: HLJ1 expression inhibited lung cancer cell proliferation, anchorage-independent growth, tumorigenesis, cell motility, and invasion, and slowed cell cycle progression through a novel STAT1/P21(WAF1) pathway that is independent of P53 and interferon.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Non-Small-Cell Lung / mortality. HSP40 Heat-Shock Proteins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / mortality
  • [MeSH-minor] Blotting, Northern. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Movement. Cell Proliferation. Cyclin D1 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Disease Progression. Disease-Free Survival. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Microsatellite Repeats. Neoplasm Recurrence, Local / epidemiology. Odds Ratio. Oligonucleotide Array Sequence Analysis. RNA, Small Interfering. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. STAT1 Transcription Factor / analysis. Survival Analysis. Transfection

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Jun 21;98(12):800-1 [16788148.001]
  • (PMID = 16788156.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNAJB4 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / RNA, Small Interfering; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 136601-57-5 / Cyclin D1
  •  go-up   go-down


60. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP, Goodglick L: A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res; 2008 Mar 1;14(5):1355-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
  • We have previously shown that the expression of several tissue kallikreins is significantly altered at the transcriptional level in lung cancer.
  • Here, we examined the clinical value of 11 members of the tissue kallikrein family as potential biomarkers for lung cancer diagnosis.
  • EXPERIMENTAL DESIGN: Serum specimens from 51 patients with non-small cell lung cancer (NSCLC) and from 50 healthy volunteers were collected.
  • The receiver operating characteristic curve of KLK4, KLK8, KLK10, KLK11, KLK12, KLK13, and KLK14 combined exhibited an area under the curve of 0.90 (95% confidence interval, 0.87-0.97).
  • CONCLUSIONS: We propose a multiparametric panel of kallikrein markers for lung cancer diagnosis with relatively good accuracy.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Tissue Kallikreins / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / blood. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / pathology. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. ROC Curve

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-86366; United States / NCI NIH HHS / CA / P50-CA90388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.35 / Tissue Kallikreins
  •  go-up   go-down


61. Hastings RH, Laux AM, Casillas A, Xu R, Lukas Z, Ernstrom K, Deftos LJ: Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients. Clin Cancer Res; 2006 Jan 15;12(2):499-506
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients.
  • PURPOSE: Parathyroid hormone-related protein (PTHrP) is commonly expressed in non-small cell lung carcinomas (NSCLC).
  • Expression of the protein could have implications for progression of the disease because it regulates cancer cell growth, apoptosis, and angiogenesis.
  • Sex-dependent effects of PTHrP in lung cancer would open new avenues of research into the role of sex in cancer progression.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Parathyroid Hormone-Related Protein / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2006 Jul 1;12(13):4130
  • (PMID = 16428492.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 23100
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


62. Coleman AM, Rendon BE, Zhao M, Qian MW, Bucala R, Xin D, Mitchell RA: Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol; 2008 Aug 15;181(4):2330-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase.
  • Recent studies have revealed that macrophage migration inhibitory factor (MIF) expression is increased in lung cancer, particularly non-small cell lung carcinomas (NSCLC).
  • Importantly, HUVEC migration and tube formation induced by supernatants from lung adenocarcinoma cells lacking either or both MIF and D-DT are substantially reduced when compared with normal supernatants.
  • This is the first demonstration of a biological role for D-DT, and its synergism with MIF suggests that the combined therapeutic targeting of both family members may enhance current anti-MIF-based therapies.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Jul;242(1):55-63 [15973102.001]
  • [Cites] Oncogene. 1999 Feb 18;18(7):1447-56 [10050881.001]
  • [Cites] Nat Med. 2005 Sep;11(9):992-7 [16127434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17751-6 [16314559.001]
  • [Cites] Oncogene. 2006 Jun 15;25(25):3501-8 [16449971.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5346-55 [17000667.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7211-24 [17082639.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):186-93 [17210698.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R132 [16872482.001]
  • [Cites] Lung Cancer. 2007 May;56(2):167-74 [17207890.001]
  • [Cites] J Rheumatol. 2007 May;34(5):927-36 [17407222.001]
  • [Cites] Nat Med. 2007 May;13(5):587-96 [17435771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13408-13 [17686984.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):29910-8 [17709373.001]
  • [Cites] Methods Enzymol. 2007;435:355-69 [17998063.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7333-45 [17533374.001]
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):147-57 [18171602.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):211-6 [11089976.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7549-55 [11390510.001]
  • [Cites] Exp Cell Res. 2001 Jun 10;266(2):203-12 [11399048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):345-50 [11756671.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):126-8 [11784881.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L690-9 [12225945.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3755-60 [12473586.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):729-37 [12576442.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):853-60 [12576459.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1467-76 [12782713.001]
  • [Cites] Biochemistry. 1999 Mar 16;38(11):3268-79 [10079069.001]
  • [Cites] Mol Med. 1999 Mar;5(3):181-91 [10404515.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):313-23 [15541816.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):22-9 [12925952.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1676-83 [14581488.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Mar;149(2):98-106 [15036884.001]
  • [Cites] Oncogene. 2004 May 20;23(23):4146-54 [15064733.001]
  • [Cites] Science. 1966 Jul 1;153(3731):80-2 [5938421.001]
  • [Cites] Cytokine. 1992 Sep;4(5):347-52 [1420995.001]
  • [Cites] J Exp Med. 1994 Jun 1;179(6):1895-902 [8195715.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5191-6 [8643551.001]
  • [Cites] Mol Med. 1996 Jan;2(1):143-9 [8900542.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):465-72 [9691082.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):375-84 [10027396.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1197-205 [16002723.001]
  • (PMID = 18684922.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI042310; United States / NIAID NIH HHS / AI / R56 AI042310; United States / NCI NIH HHS / CA / CA102285-03S1; United States / NCI NIH HHS / CA / CA102285-S; United States / NCI NIH HHS / CA / CA102285; United States / NCI NIH HHS / CA / R01 CA102285-03S1; United States / NCI NIH HHS / CA / R01 CA102285-04; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NCI NIH HHS / CA / R01 CA102285; United States / NCI NIH HHS / CA / CA102285-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL8 protein, human; 0 / Interleukin-8; 0 / Macrophage Migration-Inhibitory Factors; 0 / Vascular Endothelial Growth Factor A; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human; EC 5.3.3.12 / dopachrome isomerase
  • [Other-IDs] NLM/ NIHMS104553; NLM/ PMC2709419
  •  go-up   go-down


63. Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N: Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins. Tumori; 2007 Sep-Oct;93(5):473-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
  • AIMS AND BACKGROUND: Lung cancer is one of the most common cancers and has became a predominant cause of cancer-related death throughout the world.
  • The k-ras codon 12 mutation, which is the most common lung cancer mutation, is found in 15 to 30% of all lung cancers.
  • Furthermore, the p53 gene has a very important role in the biological properties of tumor cells, and it is mutated in about 50% of non-small cell lung cancers.
  • Molecular methods may be exploited that are sensitive enough to detect small numbers of tumor cells.
  • METHODS: In the present study, we examined p53 gene mutations and k-ras codon 12 mutations from the tumor samples and surgical margins of 34 non-small-cell lung cancer patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Protein p53 / genetics. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Codon / genetics. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038880.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


64. De Castro J, Lorenzo A, Morales S, Belón J, Dorta J, Lizón J, Madroñal C, Gallurt PM, Casado E, Feliu J, Barón MG, Oncopaz Cooperative Group: Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol; 2005 Feb;55(2):197-202
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
  • PURPOSE: To evaluate the efficacy and toxicity profile of the combination of docetaxel and prolonged gemcitabine infusion in front-line chemonaive patients with advanced non-small-cell lung cancer (NSCLC).
  • Of the 50 patients, 28 (56%) had squamous cell carcinoma, 14 adenocarcinoma (28%), and 8 (16%) large-cell carcinoma, and 40% and 60% of patients presented with stage IIIB and IV disease, respectively.
  • CONCLUSIONS: Prolonged gemcitabine infusion combined with docetaxel is well tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15322824.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


65. Tham CK, Choo SP, Lim WT, Toh CK, Leong SS, Tan SH, Li HH, Tan EH: Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. J Thorac Oncol; 2009 Aug;4(8):988-93
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
  • INTRODUCTION: Randomized placebo-controlled phase III trials failed to show a survival benefit with the addition of gefitinib to platinum-based combination chemotherapy as first-line therapy in unselected patients with advanced non-small cell lung cancer (NSCLC).
  • Most patients were women, and adenocarcinoma was the most common histologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546820.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; S65743JHBS / gefitinib
  •  go-up   go-down


66. Rubio JC, Vázquez S, Vázquez F, Amenedo M, Fírvida JL, Mel JR, Huidobro G, Alvarez E, Lázaro M, Alonso G, Fernández I, Galician Group of Lung Cancer (GGCP in the Spanish acronym): A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol; 2009 Jul;64(2):379-84
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
  • PURPOSE: To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139896.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


67. Johnson K, Berger A, Watkins T, Cheadle C, Casciola-Rosen L, Levine SM: Gene set enrichment analysis to evaluate expression of autoantigens in lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene set enrichment analysis to evaluate expression of autoantigens in lung cancer.
  • METHODS: Tumor tissue from ten lung cancer biopsies (adenocarcinoma (4), carcinoid (4), and squamous cell carcinoma (2)) and normal lung from the same patients were obtained.
  • RESULTS: Single-linkage hierarchical clustering analysis reveals groups of autoantigens that are differentially expressed between normal lung tissue, carcinoid tumors, and adenocarcinomas.
  • Adenocarcinoma tumor samples were significantly enriched for myositis (nominal p-value <0.001, false discovery rate (FDR) q-value 0.009) and SLE autoantigens (p-value 0.004, FDR 0.029).
  • While autoantigens comprise only a small fraction of the total transcriptome, they are disproportionately expressed in tumors known to associate with autoimmunity, supporting the hyporthesis that autoimmunity to these proteins may arise via nascent anti-tumor responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963230.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B: Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):318-28
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
  • PURPOSE: To evaluate prospectively the acute and late morbidities from a multiinstitutional three-dimensional radiotherapy dose-escalation study for inoperable non-small-cell lung cancer.
  • Patients were stratified at escalating radiation dose levels depending on the percentage of the total lung volume that received >20 Gy with the treatment plan (V(20)).
  • RESULTS: The following acute Grade 3 or worse toxicities were observed for Group 1: 70.9 Gy (1 case of weight loss), 77.4 Gy (nausea and hematologic toxicity in 1 case each), 83.8 Gy (1 case of hematologic toxicity), and 90.3 Gy (3 cases of lung toxicity).
  • The following acute Grade 3 or worse toxicities were observed for Group 2: none at 70.9 Gy and 2 cases of lung toxicity at 77.4 Gy.
  • The estimated rate of Grade 3 or worse late lung toxicity at 18 months was 7%, 16%, 0%, and 13% for Group 1 patients receiving 70.9, 77.4, 83.8, or 90.3 Gy, respectively.
  • Group 2 patients had an estimated late lung toxicity rate of 15% at 18 months for both 70.9 and 77.4 Gy.
  • The prognostic factors for late pneumonitis in multivariate analysis were the mean lung dose and V(20).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667949.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


69. Xu JB, Bao Y, Liu X, Liu Y, Huang S, Wang JC: Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma. Lung Cancer; 2007 Oct;58(1):36-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
  • Large cell carcinoma (LCC) of the lung is defined as an undifferentiated carcinoma without the characteristic features of squamous cell (SqC), small cell, or adenocarcinomas (AdC).
  • In the present study, the expression level of the important tumor suppressor, transforming growth factor beta type II receptor (TGFBR2), was examined both in LCC and non-LCC tumors, which include AdC, SqC and adenosquamous carcinoma (Ad-SqC).
  • [MeSH-major] Carcinoma, Large Cell / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Biomarkers, Tumor. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Neoplasm Staging

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566598.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


70. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, Popat S: Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol; 2010 Apr;5(4):436-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
  • INTRODUCTION: The dichotomization of non-small cell carcinoma (NSCLC) subtype into squamous (SQCC) and adenocarcinoma (ADC) has become important in recent years and is increasingly required with regard to management.
  • The aim of this study was to determine the utility of a panel of commercially available antibodies in refining the diagnosis on small biopsies and also to determine whether cytologic material is suitable for somatic EGFR genotyping in a prospectively analyzed series of patients undergoing investigation for suspected lung cancer.
  • This included 10 of 13 cases where cell pellets had been prepared from transbronchial needle aspirates.
  • Validation by two further pathologists with varying expertise in lung pathology confirmed increased refinement and concordance of diagnosis.
  • These small samples, even cell pellets derived from transbronchial needle aspirates, seem to be adequate for EGFR mutation analysis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Mucins / metabolism. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Biopsy, Fine-Needle. Cytodiagnosis / methods. DNA Mutational Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Genotype. Humans. Immunoenzyme Techniques. Keratin-5 / metabolism. Keratin-6 / metabolism. Mutation / genetics. Neoplasm Staging. Nuclear Proteins / metabolism. Polymerase Chain Reaction. Prognosis. Prospective Studies. Retrospective Studies. Sensitivity and Specificity. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / genetics. Small Cell Lung Carcinoma / metabolism. Survival Rate. Trans-Activators / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Apr;5(4):411-4 [20357614.001]
  • (PMID = 20068475.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Keratin-5; 0 / Keratin-6; 0 / Mucins; 0 / Nuclear Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / thyroid nuclear factor 1; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


71. Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D: Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. J Thorac Oncol; 2010 Apr;5(4):491-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
  • INTRODUCTION: The aim of this study was to describe the characteristics and epidermal growth factor receptor (EGFR) mutational status of patients with non-small cell lung cancer (NSCLC) with osteoblastic reactions diagnosed before or during treatment with EGFR tyrosine kinase inhibitors (TKIs).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Osteoblasts / drug effects. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. DNA Mutational Analysis. DNA, Neoplasm / genetics. Erlotinib Hydrochloride. Female. Genotype. Humans. Male. Middle Aged. Mutation / genetics. Neoplasm Staging. Polymerase Chain Reaction. Quinazolines / administration & dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Apr;5(4):415-6 [20357615.001]
  • (PMID = 20195171.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


72. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, Uliano M: The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer; 2010 Aug;69(2):187-93
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
  • The optimal cut-off values of SUVmax to predict prognosis were 5 for adenocarcinoma (p=0.027) and 10.7 for other non-adenocarcinoma NSCLC subtypes (p=0.010).
  • These histologic-specific cut-offs resulted significantly related to survival when stratified for stage: 2-year DSS for Stage IB adenocarcinoma were 100% for SUV< or =5 and 40% for SUVmax >5 (p=0.051); 2-year DSS for Stage IB non-adenocarcinoma were 83% for SUVmax < or =10.7 and 26% for SUVmax >10.7 (p=0.018).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19942313.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


73. Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Hasegawa S, Fukuoka K, Nakano T: Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer.
  • : 11066 Background: Circulating tumor cell (CTC), a surrogate of distant metastasis, and circulating endothelia cell (CEC), a surrogate of angiogenesis, are potentially useful in the diagnosis of malignant tumors, but clinical significance of CTC/CEC in primary lung cancer (LC) remains unclear.
  • RESULTS: In 42 (30.7%) of 137 LC cases, CTC in the peripheral blood was positive (CTC-count, more than 1 cell/7.5mL), and the maximum CTC-count was 62 cells.
  • In 11 (18.3%) of 145 cases with non-malignant (NM) diseases, CTC was also positive; however, in NM cases, CTC-count was 1 (cell/7.5mL) in most CTC-positive cases and the maximun CTC-count was 2.
  • Among LC cases, the incidence of case with CTC-positive (CTC-count, 1 or more) was highest in small cell carcinoma cases (7/10, 70.0%), followed by squamous cell carcinoma (9/22, 40.9%) and adenocarcinoma (23/94, 24.5%) cases; the incidence of CTC-positive case was significantly higher in stage IV cases (68.6%; p<0.001), but it should be noted that CTC was positive in 17.4% of stage I cases and 15.4% of stage II cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Song P, Spindel ER: Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci; 2008 Feb;106(2):180-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy.
  • Lung cancer is the leading cause of cancer death worldwide and new treatment strategies are clearly needed.
  • The recent discovery that lung and other cancers synthesize and secrete acetylcholine (ACh) which acts as an autocrine growth factor suggests that this cholinergic autocrine loop may present new therapeutic targets.
  • In normal bronchial epithelium, small airway epithelium and pulmonary neuroendocrine cells synthesize Ach; and in squamous cell lung carcinoma, adenocarcinoma, and small cell lung carcinoma, the respective lung cancers that derive from those cell types similarly synthesize ACh.
  • ACh secreted by those cancers stimulates growth of the tumors by binding to nicotinic and muscarinic receptors expressed on lung cancers.
  • Thus antagonists to nicotinic and muscarinic receptors can inhibit lung cancer growth.
  • The muscarinic receptor (mAChR) subtype utilized for cell proliferation is the M(3) subtype and consistent with this M(3) mAChR antagonists inhibit growth of SCLC and squamous cell carcinomas.
  • As multiple other cancer types besides lung carcinomas express both M(3) mAChR and acetylcholine, other cancer types besides lung carcinoma may respond to M(3) mAChR antagonists.
  • [MeSH-major] Acetylcholine / metabolism. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285655.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Receptor, Muscarinic M3; N9YNS0M02X / Acetylcholine
  • [Number-of-references] 21
  •  go-up   go-down


75. Lin PY, Chang YC, Chen HY, Chen CH, Tsui HC, Yang PC: Tumor size matters differently in pulmonary adenocarcinoma and squamous cell carcinoma. Lung Cancer; 2010 Mar;67(3):296-300
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor size matters differently in pulmonary adenocarcinoma and squamous cell carcinoma.
  • Little about primary tumor size and nodal/distant metastases among different cell types in non-small cell lung cancer (NSCLC) was discussed.
  • This study aimed to investigate distinct associations between tumor size and nodal/distant metastases in pulmonary adenocarcinoma and squamous cell carcinoma.
  • Our data showed that 2.5 cm was the critical cutoff size regarding increased nodal/distant metastases in adenocarcinoma (p<0.001), but not in squamous cell carcinoma (p>0.05).
  • In addition, the incidence of nodal/distant metastases reached a plateau of more than 80% in adenocarcinoma when the tumor size exceeded 2.5 cm.
  • In contrast, there was no such correlation observed in squamous cell carcinoma.
  • This study showed that tumor size mattered differently in pulmonary adenocarcinoma and squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473720.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


76. Yamauchi S, Kudoh S, Kimura T, Yoshimura N, Mukohara T, Hirata K, Yoshikawa J: The association of adenocarcinoma and hemosputum in pulmonary malignancies. Respiration; 2005 Sep-Oct;72(5):499-503
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of adenocarcinoma and hemosputum in pulmonary malignancies.
  • BACKGROUND: Hemosputum was considered one of the popular symptoms of patients with centrally located carcinoma of the lung, especially squamous cell or small cell type.
  • Recent studies reported a relative increase in adenocarcinoma compared with squamous cell carcinoma, especially in developed countries.
  • There were 66 patients with adenocarcinoma, 55 with squamous cell carcinoma, 15 with small cell carcinoma, 5 with large cell carcinoma, 3 with other cell type carcinoma and 5 with metastatic carcinoma.
  • On bronchoendoscopic examination, abnormal findings in the segmental or more proximal bronchi were found in 82 patients, including 36 with squamous cell carcinoma, 31 with adenocarcinoma, 12 with small cell carcinoma, 2 with large cell carcinoma and 1 with metastatic carcinoma.
  • On the other hand, 67 patients were diagnosed with pulmonary malignancy in the subsegmental or more distal area, including 35 with adenocarcinoma, 19 with squamous cell carcinoma, 3 with small cell carcinoma, 3 with large cell carcinoma, 3 with other cell type carcinoma and 4 with metastatic carcinoma.
  • CONCLUSIONS: The most frequent histological type of malignancy with hemosputum was adenocarcinoma.
  • The number of adenocarcinoma with hemosputum was increased in both central and peripheral regions.
  • [MeSH-major] Carcinoma / pathology. Hemoptysis / etiology. Lung Neoplasms / pathology. Sputum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16210889.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


77. Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, Koss MN, Pass HI, Hagen JA, Laird-Offringa IA: Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer; 2005 Feb;47(2):193-204
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung.
  • In particular when limited cell numbers are available, amplifyable DNA markers can provide a very sensitive tool for cancer detection and classification.
  • Malignant mesothelioma (MM), an aggressive cancer strongly associated with asbestos exposure, can be difficult to distinguish from adenocarcinoma of the lung when limited material is available.
  • In an attempt to identify molecular markers for MM and adenocarcinoma, we examined the DNA methylation status of 14 loci.
  • Analysis of methylation levels in 10 MM and 8 adenocarcinoma cell lines showed that methylation of APC was significantly elevated in adenocarcinoma compared to MM cell lines (P=0.0003), while methylation of CDH1 was higher in MM (P<0.02).
  • Subsequent examination of the methylation status of the 14 loci in 6 MM and 7 adenocarcinoma primary tumors, which yielded similar methylation profiles, supported these observations.
  • Comparison of methylation in MM cell lines and tumors versus non-tumor lung tissue indicated that APC exhibits less methylation in MM (P=0.003) while RASSF1, PGR1, ESR1, and CDH1 show more methylation in MM, the latter two showing the most significant difference between the two tissue types (P< or = 0.0001).
  • Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).
  • Thus, with the examination of 14 loci, we have identified 5 candidates that show potential for distinguishing between MM, adenocarcinoma and/or non-cancer lung.
  • Our observations support the strong potential of methylation markers as tools for accurate diagnosis of neoplasms in and around the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. DNA, Neoplasm. Genetic Markers. Lung Neoplasms / genetics. Mesothelioma / genetics
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Lung. Sensitivity and Specificity. Tumor Cells, Cultured


78. Davidson JA, Wong V, Fraser R, Hirsh V: Comparison of primary tumor maximal standardized uptake value (SUV&lt;sub&gt;max&lt;/sub&gt;) on preoperative [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and histological subtype in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of primary tumor maximal standardized uptake value (SUV<sub>max</sub>) on preoperative [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and histological subtype in patients with non-small cell lung cancer (NSCLC).
  • Only patients with Adenocarcinoma (AC), Squamous Cell carcinoma (SC), or Large Cell carcinoma (LC), and definitive pathological staging, were included.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963356.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Bai XY, Shen H: [Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct;26(10):1423-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray].
  • OBJECTIVE: To investigate thyroid transcription factor-1 (TTF-1) expression in normal human adult type II alveolar epithelial cells, embryonic pneumocytes, lung carcinoma cells and lymph node metastases of lung cancer.
  • METHODS: Lung carcinoma tissue microarray was constructed containing 765 cores of 20 normal adult lung tissues, 15 embryonic lung tissues, 100 lung carcinomas and 55 corresponding lymph node metastases.
  • The nuclei of lung carcinoma cells had smaller TTF-1 PU than normal adult type II alveolar epithelial cells and embryonic pneumocyte nuclei (P<0.001).
  • The lung adenocarcinoma and small cell lung carcinoma cell nuclei had greater TTF-1 PU than squamous cell carcinoma and large cell lung carcinoma cell nuclei (P<0.001).
  • TTF-1 PU was greater in squamous cell carcinoma cell nuclei than in large cell lung carcinoma cell nuclei (P<0.001).
  • In lung adenocarcinoma, squamous cell lung carcinoma and large cell lung carcinoma, TTF-1 PU was greater in the cancerous cell nuclei of lymph node metastases than in the corresponding primary carcinoma cell nuclei (P<0.001, P<0.001, and P<0.05, respectively).
  • In small cell lung carcinoma, TTF-1 PU of the cancerous cell nuclei of lymph node metastases was similar to that of primary carcinomas (P>0.05).
  • TTF-1 PU was greater in lung carcinoma with lymph node metastases than in those without metastalsis (P<0.001).
  • TTF-1 PU of the cell nuclei was not associated with the tumor growth pattern, differentiation and patients' gender (P>0.05), but was greater in TNM stage II-IV than in stage I (P<0.001).
  • CONCLUSIONS: The amount of TTF-1 in the cell nuclei decreases in the order of normal adult type II alveolar epithelial cells, embryonic pneumocytes and lung carcinoma cells.
  • TTF-1 expression is higher in adenocarcinoma and small cell carcinoma and lower in squamous carcinoma and large cell carcinoma.
  • Stronger TTF-1 expression is associated with greater likeliness of lung carcinoma metastatie, and can be an important hallmark for metastasis potential of lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
  • [MeSH-major] Cell Nucleus / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Tissue Array Analysis / methods. Transcription Factors / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


80. Muehlenbein CE, Klein RW, Liepa AM, Babineaux SM, Wielage RC, Schwartzberg LS: The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e17533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer.
  • : e17533 Background: A recent randomized phase III study was the first to report survival differences between first-line platinum doublets based on non-small cell lung cancer (NSCLC) histology (Scagliotti et al, J Clin Oncol. 2008).
  • Nonsquamous histology subgroups explored were adenocarcinoma, large cell and not otherwise specified (NOS).
  • In the subset of patients with nonsquamous NSCLC (adenocarcinoma, large cell, or NOS), the incremental cost per LYG was $83,537 vs. Cis/Gem and $178,613 vs. Carb/Pac.
  • Further specifying the population to include only those with adenocarcinoma or large cell NSCLC yielded an incremental cost per LYG of $72,325 vs. Cis/Gem and $132,547 vs. Carb/Pac.
  • CONCLUSIONS: In an unselected advanced NSCLC population, Cis/Pem may not be considered cost-effective for first-line therapy; however, in its licensed indication of nonsquamous NSCLC, it can be considered cost-effective and even more so for patients with adenocarcinoma or large cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963793.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Mitsuta K, Yokoyama A, Kondo K, Nakajima M, Arita K, Kohno N: Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis. Oncol Rep; 2005 Jul;14(1):185-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis.
  • We hypothesize that MUC1 allele length polymorphism (variable number of tandem repeats) is associated with development of lung adenocarcinoma.
  • We evaluated MUC1 gene polymorphism using Southern blot analysis of peripheral blood from patients with non-small cell lung cancer (n=56), patients with benign respiratory disease (n=52), and healthy volunteers (n=52).
  • We found that large MUC1 allele length was significantly associated with lung adenocarcinoma but not with squamous cell carcinoma of the lung.
  • Adenocarcinoma patients with a homozygous large MUC1 genotype had a worse prognosis than patients with a heterozygous (large + small) MUC1 genotype or a homozygous small MUC1 genotype.
  • These results suggest that the large MUC1 allele is associated with susceptibility to lung adenocarcinoma and poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Genetic Predisposition to Disease / genetics. Lung Neoplasms / pathology. Mucin-1 / genetics. Polymorphism, Genetic
  • [MeSH-minor] Aged. Aged, 80 and over. Alleles. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Gene Frequency. Genotype. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944787.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


82. Yoshino I, Osoegawa A, Yohena T, Kameyama T, Oki E, Oda S, Maehara Y: Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma. Respir Med; 2005 Mar;99(3):308-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma.
  • BACKGROUND: In non-small cell lung cancer, a loss of heterozygosity (LOH) is frequently observed; however, few studies have investigated the differences in the LOH status between adenocarcinoma and squamous cell carcinoma.
  • PATIENTS AND METHODS: In a consecutive series of 49 patients with adenocarcinomas and 22 patients with squamous cell carcinomas, the LOH in tumors was analyzed using polymerase chain reaction employing 5 fluorescence-labeled dinucleotide markers (D2S123, D5S107, D10S197, D11SS904, D13S175) and an autosequencer.
  • RESULTS: LOH was more frequently observed in squamous cell carcinoma (20 of 22, 90%) than in adenocarcinomas (33 of 49, 67%) (P=0.0348), and the number of LOH per patient was also higher in the patients with squamous cell carcinoma (2.2+/-1.4) than in those with adenocarcinoma (1.5+/-1.2, P=0.037).
  • In adenocarcinomas, the number of LOH per patients correlated significantly with the pack-year index, whereas the pathological stage significantly affected the number of LOH in squamous cell carcinomas.
  • CONCLUSION: The presence of LOH is relatively uncommon in adenocarcinoma of the lung; however, the incidence of LOH tends to be associated with the smoking status.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Loss of Heterozygosity / genetics. Lung Neoplasms / genetics


83. Meng X Jr, Yu JM, Yang GR, Zhao SQ, Sun XD: &lt;sup&gt;11&lt;/sup&gt;C-PD153035 PET/CT molecular imaging of EGFR for evaluation of advanced non-small cell lung cancer (NSCLC) to EGFR-targeted therapy. J Clin Oncol; 2009 May 20;27(15_suppl):7576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <sup>11</sup>C-PD153035 PET/CT molecular imaging of EGFR for evaluation of advanced non-small cell lung cancer (NSCLC) to EGFR-targeted therapy.
  • RESULTS: 12 patients (5 men, 7 women; age range, 60-79 years) have been enrolled in this study from August 2008, including 3 cases of squamous cell carcinoma, 1 case of large cell carcinoma, and the other of adenocarcinoma.
  • Tumor/lung ratio at 20 min was 4.14 ± 1.80.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963384.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Saji H, Tsuboi M, Miyajima K, Shimada Y, Ohira T, Ikeda N: Impact of number of resected and involved lymph nodes (LN) at the time of surgical resection on the survival of non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of number of resected and involved lymph nodes (LN) at the time of surgical resection on the survival of non-small cell lung cancer (NSCLC).
  • RESULTS: Demographics are as follows: median age: 65.0 (22-87yrs), sex: 547 males and 381 females, median follow-up time: 2.5 yrs, clinical stage: 765 stage I, 84 stage II and 76 stage III, histology: 684 adenocarcinoma, 182 squamous cell carcinoma, and 62 others, operation: 870 lobectomy, 42 bilobectomy and 16 pneumonectomy, mean number of resected LN: 15 (1-49), mean number of involved LN: 0.9 (0-22).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Qiu Y, Song B, Zhao G, Deng B, Makino T, Tomita Y, Wang J, Luo W, Doki Y, Aozasa K, Morii E: Expression level of Pre B cell leukemia homeobox 2 correlates with poor prognosis of gastric adenocarcinoma and esophageal squamous cell carcinoma. Int J Oncol; 2010 Mar;36(3):651-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression level of Pre B cell leukemia homeobox 2 correlates with poor prognosis of gastric adenocarcinoma and esophageal squamous cell carcinoma.
  • Pre B cell leukemia homeobox 2 (PBX2), a member of PBX family, acts as a co-factor of homeobox proteins to regulate proliferation and differentiation of tumor cells.
  • Our recent study revealed prognostic significance of PBX2 expression in non-small cell lung carcinoma.
  • The significance of PBX2 expression was examined in cases with gastric cancer (GC) and esophageal squamous cell carcinoma (ESCC), and the role of PBX2 in tumor behavior was evaluated in GC and ESCC cell lines of knocked-down PBX2 expression.
  • Knocked-down expression of PBX2 in GC and ESCC cell lines resulted in decrease of in vitro colony formation and in vivo tumorigenic activities, but proliferative and invasive activities did not change.
  • Under serum depletion, apoptotic cell proportion was higher in PBX2 knocked-down cells than in control cells.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Cell Differentiation. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20126986.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / PBX2 protein, human; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


86. Yu J, Liu N, Hu M, Song X, Xie L, Meng X, Wang X, Kong L, Yang G: Further evaluation of &lt;sup&gt;11&lt;/sup&gt;C-PD153035 as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in non-small cell lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):3590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Further evaluation of <sup>11</sup>C-PD153035 as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in non-small cell lung cancer patients.
  • Our pilot study has demonstrated that <sup>11</sup>C-PD153035, a highly EGFR selective tracer for positron emission tomography (PET), accumulated in tumor mass of non-small cell lung cancer (NSCLC) and the tracer uptake correlated with EGFR expression.
  • METHODS: Fourteen patients (45-71y, mean 59.2±9.2 y, Male: Female = 8:6, squamous carcinoma: adenocarcinoma = 9:5) with pathologically proved NSCLC were examined with PET using <sup>11</sup>C-PD153035 one week before surgery.
  • CONCLUSIONS: PET with <sup>11</sup>C-PD153035 might therefore be used to visualize EGFR pattern on tumor in NSCLC patients and for individualized planning of therapeutic strategies with EGFR targeted drugs, especially small-molecule TKIs (gefitinib and erlotinib) which targeting the intracellular EGFR tyrosine kinase domain as PD153035.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg; 2010 Apr;139(4):984-90; discussion 990
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung.
  • OBJECTIVE: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC).
  • This study tested the hypothesis that a differential MMP profile would exist between NSCLC and normal lung and that MMP patterns would differ between NSCLC histologic types.
  • METHODS: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics.
  • For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05).

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):45-56 [16680571.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):941-6 [16538215.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5448-53 [17000679.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2054-60 [17404086.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):52-60 [17625931.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1362-78 [18258475.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1188-94 [18422740.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2185-92 [18823373.001]
  • [Cites] Ann Thorac Surg. 2008 Nov;86(5):1576-83 [19049753.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):67-74 [19331134.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):894-901 [19480010.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2513-7 [19596921.001]
  • [Cites] J Pathol. 2000 Feb;190(2):150-6 [10657012.001]
  • [Cites] Circulation. 2000 Oct 17;102(16):1944-9 [11034943.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3944-8 [11051242.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):421-4 [11182067.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):647-51 [12494473.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):745-51 [12866035.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3098-104 [12912961.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):541-50 [14520690.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):171-9 [15246188.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):461-9 [9234385.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):149-53 [9918213.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):842-9 [15681529.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1086-92 [15709175.001]
  • [Cites] Circulation. 2005 Mar 8;111(9):1166-74 [15723986.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):245-52 [15592677.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1676-84 [15754326.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] Anal Biochem. 2005 Aug 1;343(1):54-65 [15953581.001]
  • [Cites] Am J Cardiol. 2006 Feb 15;97(4):532-7 [16461051.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):313-21 [16423426.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Circulation. 2006 Jul 4;114(1 Suppl):I365-70 [16820601.001]
  • (PMID = 20304142.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL059165; United States / NHLBI NIH HHS / HL / R01 HL059165-11; United States / NHLBI NIH HHS / HL / HL59165; United States / NHLBI NIH HHS / HL / HL81691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS167053; NLM/ PMC2844342
  •  go-up   go-down


88. Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y, Koizumi K, Nakazawa N, Ishiwata T, Naito Z: Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int J Oncol; 2008 Dec;33(6):1177-85
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma.
  • Lumican is a member of a small leucine-rich proteoglycan family and is highly expressed in several types of cancer cells and/or stromal tissue.
  • In this study, we examined the expression and role of lumican in lung cancer including adenocarcinoma (ADC) and squamous cell carcinoma (SqCC).
  • Immunohistochemically, lumican was weakly expressed in vascular smooth muscle cells, perivascular and peribronchial connective tissues and bronchial epithelium of normal lung tissues.
  • In lung cancer tissues, lumican was localized in the cytoplasm of cancer cells and/or stromal tissues adjacent to cancer cells.
  • In lung cancer cell lines, lumican mRNA and protein were expressed in LC-1/Sq and EBC-1 cells established from SqCC, and A549, RERF-LC-KJ and PC-3 cells from ADC.
  • The molecular weight of lumican extracted from the cytoplasm of lung cancer cells differed from that in the culture medium owing to glycosylation of the protein.
  • These findings suggest that the expression pattern and the glycosylated type of lumican in cells and stromal tissues correlate with the aggressiveness of lung SqCC and ADC.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Chondroitin Sulfate Proteoglycans / metabolism. Keratan Sulfate / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Cell Line, Tumor. Cytoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Glycosylation. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / metabolism. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020750.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chondroitin Sulfate Proteoglycans; 0 / RNA, Messenger; 0 / lumican; 9056-36-4 / Keratan Sulfate
  •  go-up   go-down


89. Fontinele e Silva J, Barbosa Mde P, Viegas CL: Small cell carcinoma in Pancoast syndrome. J Bras Pneumol; 2009 Feb;35(2):190-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma in Pancoast syndrome.
  • The majority of cases of Pancoast syndrome are caused by bronchogenic carcinoma.
  • The most commonly found histologic subtypes are adenocarcinoma and epidermoid carcinoma.
  • There have been very few reports of small cell lung carcinoma in the genesis of Pancoast syndrome.
  • We describe the case of a patient with Pancoast syndrome caused by small cell lung carcinoma and discuss the aspects related to the diagnosis and treatment.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Lung / pathology. Pancoast Syndrome / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287924.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


90. Oizumi S, Akie K, Ogura S, Shinagawa N, Fukumoto S, Harada M, Kojima T, Kinoshita I, Dosaka-Akita H, Isobe H, Nishimura M: Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group 0601. J Clin Oncol; 2009 May 20;27(15_suppl):e19012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group 0601.
  • : e19012 Background: Platinum-containing therapy is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC).
  • Median age was 64 years (range, 42-75); 29 patients (73%) had adenocarcinoma, and 8 patients (20%) had squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Tojo T, Tojo T, Naito H, Kimura M, Takasawa S, Dohi Y, Nagata Y, Taniguchi S: Regenerating gene 1α (REG 1α) expression and new treatment strategies in early non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22178

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regenerating gene 1α (REG 1α) expression and new treatment strategies in early non-small cell lung cancer.
  • In the present study, to elucidate roles for REG Iα in non-small cell lung cancer (NSCLC), we investigated REG Iα expression in NSCLCs, focusing especially on its relationship with prognosis.
  • METHODS: We enrolled 70 NSCLCs (adenocarcinoma (AC)(n=48) and squamous cell carcinoma (SCC)(n=22)) who received surgery at Nara Medical University Hospital.
  • Total RNA was extracted from each tumor tissue and corresponding normal lung tissue (NL)(n=70), cDNA was then reverse-transcribed from total RNA, and quantitative real-time reverse transcriptase-polymerase chain reaction was then carried out.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963718.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Shimada A, Kano J, Ishiyama T, Okubo C, Iijima T, Morishita Y, Minami Y, Inadome Y, Shu Y, Sugita S, Takeuchi T, Noguchi M: Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci; 2005 Oct;96(10):668-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development.
  • Atypical adenomatous hyperplasia (AAH) is classified as a precancerous lesion of lung adenocarcinoma.
  • We established an immortalized AAH cell line (PL16T) and a human non-neoplastic bronchial epithelial cell line (PL16B) from the same patient by transfection with the gene for SV40 large T antigen.
  • In normal lung tissue, both TACSTD2 and S100A2 were expressed at very low levels, but seven and five of 14 AAH were positive for TACSTD2 and S100A2, respectively.
  • The frequency of TACSTD2 positivity was increased in 16 of 22 bronchioloalveolar carcinomas (BAC) and adenocarcinoma with mixed subtype with BAC component (mixed BAC).
  • The abnormal transcription of TACSTD2 and S100A2 are thought to be unique molecular markers of the preinvasive stage of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / biosynthesis. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Cell Adhesion Molecules / biosynthesis. Chemotactic Factors / biosynthesis. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Precancerous Conditions / genetics. Precancerous Conditions / pathology. S100 Proteins / biosynthesis
  • [MeSH-minor] Female. Gene Expression Profiling. Humans. Hyperplasia. Lung / pathology. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16232198.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / Chemotactic Factors; 0 / S100 Proteins; 0 / S100A2 protein, human; 0 / TACSTD2 protein, human
  •  go-up   go-down


93. Bugalho P, Chorão M, Fontoura P: Miliary brain metastases from primary gastric small cell carcinoma: illustrating the seed and soil hypothesis. J Neurooncol; 2005 May;73(1):53-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miliary brain metastases from primary gastric small cell carcinoma: illustrating the seed and soil hypothesis.
  • Miliary metastases are a very rare condition usually found in the context of primary lung tumor (small cell and adenocarcinoma), and refer to the existence of numerous tumor nodules in widespread areas of the brain.
  • Besides pulmonary neoplasia, pancreatic adenocarcinoma and malignant melanoma have also been implicated in some cases of miliary metastases.
  • We present the first case of miliary metastases originating in a primary small cell gastric carcinoma (PSCGC), a rare type of neuroendocrine gastric tumor.
  • The pathological resemblance of PSCGC with small cell lung carcinoma may correspond to an underlying similarity in biological behavior, which accounts for this particular pattern of metastatic spreading, as proposed in the seed and soil hypothesis.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933819.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 5W494URQ81 / Streptozocin; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Hsiao HH, Tsai HJ, Liu YC, Tseng YT, Tseng SB, Chai CY, Lin SF: A rare case of combined small-cell lung cancer with unusual soft tissue metastasis. Kaohsiung J Med Sci; 2006 Jul;22(7):352-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of combined small-cell lung cancer with unusual soft tissue metastasis.
  • Combined small-cell lung carcinoma (SCLC) is a rare tumor.
  • We report a case of combined SCLC of the lung, including adenocarcinoma and spindle-shaped cell tumor, with an unusual initial presentation.
  • A lung nodule was noted later after complete examination.
  • The diagnosis turned out to be combined cell carcinoma with three different components (small-cell carcinoma, adenocarcinoma, and spindle-shaped cell tumor) after examination upon total removal of the lung nodule by lobectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma / pathology. Carcinoma, Small Cell / pathology. Lung Neoplasms / pathology. Soft Tissue Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849104.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


95. Uchihara T, Okubo C, Tanaka R, Minami Y, Inadome Y, Iijima T, Morishita Y, Fujita J, Noguchi M: Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma. J Thorac Oncol; 2007 Sep;2(9):796-801
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma.
  • The purpose of this study was to clarify the significance of neuronatin expression in pulmonary non-small cell carcinoma.
  • METHODS: We determined the frequency of neuronatin expression in surgically resected samples from non-small cell lung carcinoma (51 adenocarcinoma and 41 squamous cell carcinoma) by immunohistochemical staining, and investigated the correlations between expression level and various clinicopathological features.
  • RESULTS: Expression of neuronatin was observed more frequently in squamous cell carcinoma (63%) than in adenocarcinoma (25%).
  • In most cases, nontumorous lung tissue did not react with the antibody against neuronatin.
  • In both adenocarcinoma and squamous cell carcinoma, less differentiated tumors expressed neuronatin more frequently than did differentiated tumors.
  • In adenocarcinoma, but not squamous cell carcinoma, the prognosis of neuronatin-positive cases was significantly worse than that of neuronatin-negative cases.
  • CONCLUSION: Neuronatin expression is specific for tumor tissue and was detected in both pulmonary adenocarcinoma and squamous cell carcinoma at high frequency, particularly in less differentiated tumors.
  • Neuronatin expression is associated with poor prognosis in patients with adenocarcinoma, and may be useful as a prognostic marker for lung adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung. Gene Expression Regulation, Neoplastic. Lung Neoplasms. Membrane Proteins / genetics. Nerve Tissue Proteins / genetics. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805055.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / NNAT protein, human; 0 / Nerve Tissue Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


96. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, Baek SM, Park CS, Park CM, Kim YI, Lim SC, Park KO: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res; 2005 Mar 15;11(6):2244-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of the response to gefitinib in refractory non-small cell lung cancer.
  • Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has a response rate of 10% to 20% in refractory non-small cell lung carcinoma.
  • Although female gender, adenocarcinoma, and never having smoked are possible markers of a favorable response, mutations of the EGFR gene have also been reported to be highly significant predictors of response.
  • Seventy patients with relapsed non-small cell lung carcinoma were enrolled in the Expanded Access Program.
  • The response rate was significantly higher for adenocarcinoma (41.0%) versus non-adenocarcinoma (9.8%, P = 0.001), in those who never smoked (58.8%) versus smokers (15.9%, P < 0.001), and in females (42.1%) versus males (19.7%, P = 0.049).
  • In a multivariate logistic analysis, the independent predictors of response were smoking history and adenocarcinoma.
  • Given that 9.5% of smokers and 6.7% of those with non-adenocarcinoma showed a mutation of the EGFR gene, the genetic profile may replace those variables as an independent predictor of a response.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Disease Progression. Feasibility Studies. Female. Humans. Male. Middle Aged. Mutation. Predictive Value of Tests. Prognosis. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome


97. Chen XJ, Xiao W, Qu X, Zhou SY: NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. Neoplasma; 2008;55(3):200-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
  • Gemcitabine is a chemotherapeutic drug widely used in the treatment of non-small cell lung carcinoma, especially in advanced lung adenocarcinoma.
  • However, many patients with advanced lung adenocarcinoma show a resistance to gemcitabine.
  • Overexpression of COX-2 has been found in human non-small cell lung cancer tissues and itA s cell lines.
  • However, It is unknown whether COX-2 inhibitor can augment the efficacy of gemcitabine against lung adenocarcinoma.
  • The cell viability was examined by MTT assay.
  • The cell cycle distribution and apoptotic ratio were tested by flow cytometry.
  • It can be concluded that NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma and the efficacy is associated with up-regulation of p21WAF1 and p27KIP1protein.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Cyclooxygenase 2 Inhibitors / pharmacology. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Cell Line, Tumor. Drug Synergism. Humans. Up-Regulation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348652.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitrobenzenes; 0 / Sulfonamides; 0W860991D6 / Deoxycytidine; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


98. Dejmek JS, Dejmek A: The reactivity to CK5/6 antibody in tumor cells from non-small cell lung cancers shed into pleural effusions predicts survival. Oncol Rep; 2006 Mar;15(3):583-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reactivity to CK5/6 antibody in tumor cells from non-small cell lung cancers shed into pleural effusions predicts survival.
  • Lung cancer, especially adenocarcinoma and large cell carcinoma, tends to spread to the pleural cavities.
  • Dakopatts CK 5/6 antibody was applied to ethanol-fixed fresh cytospin preparations from malignant pleural effusions originating from 18 patients (11 men and 7 women) with a previously or later verified non-small cell lung carcinoma (NSCLC).
  • The strong relationship between CK5/6 reactivity and survival, and the observed gender difference, warrants larger studies aimed at the clinical utility of CK5/6 as a prognostic marker in metastatic NSCLC, the possible functional role of CK5/6 in cell adhesion in advanced NSCLC and its possible hormonal control.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Keratins / analysis. Lung Neoplasms / pathology. Pleural Effusion / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465416.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-5; 0 / Keratin-6; 68238-35-7 / Keratins
  •  go-up   go-down


99. Yesil-Celiktas O, Sevimli C, Bedir E, Vardar-Sukan F: Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines. Plant Foods Hum Nutr; 2010 Jun;65(2):158-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines.
  • Subsequently, six extracts and the active compounds, carnosic acid, and rosmarinic acid were applied to various human cancer cell lines including NCI-H82 (human, small cell lung, carcinoma), DU-145 (human, prostate, carcinoma), Hep-3B (human, black, liver, carcinoma, hepatocellular), K-562 (human chronic myeloid leukemia), MCF-7 (human, breast, adenocarcinoma), PC-3 (human, prostate, adenocarcinoma) and MDA-MB-231 (human, breast, adenocarcinoma) by MTT assay.
  • Although the extracts exhibited various cytotoxic effects against different cell lines, comparatively low IC(50) values ranging between 12.50 and 47.55 microg/ml were attained against K-562, being the most sensitive cell line.
  • Moreover, carnosic acid caused the lowest cell viability with values ranging from 13 to 30 % at a concentration of 19 muM after 48 h of treatments, resulting in superior antiproliferative effect.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Cell Proliferation / drug effects. Cinnamates / therapeutic use. Depsides / therapeutic use. Diterpenes, Abietane / therapeutic use. Neoplasms / drug therapy. Phytotherapy. Plant Extracts / therapeutic use. Rosmarinus / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Humans. Inhibitory Concentration 50. Turkey

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. ROSMARINIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449663.001).
  • [ISSN] 1573-9104
  • [Journal-full-title] Plant foods for human nutrition (Dordrecht, Netherlands)
  • [ISO-abbreviation] Plant Foods Hum Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cinnamates; 0 / Depsides; 0 / Diterpenes, Abietane; 0 / Plant Extracts; LI791SXT24 / salvin; MQE6XG29YI / rosmarinic acid
  •  go-up   go-down


100. Iizasa T, Baba M, Saitoh Y, Suzuki M, Haga Y, Iyoda A, Chang H, Hiroshima K, Itoga S, Tomonaga T, Nomura F, Fujisawa T: A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population. Oncol Rep; 2005 Oct;14(4):919-23
Hazardous Substances Data Bank. N-NITROSODIMETHYLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population.
  • A tandem repeat polymorphism in the 5'-flanking region of the CYP2E1 gene was investigated in non-small cell lung carcinoma (NSCLC) patients to clarify the relationship between CYP2E1 gene polymorphism and lung cancer susceptibility.
  • Sequence analysis confirmed the presence of three alleles, A2, A3, and A4 (361, 367, and 457 bp, respectively), with four genotypes observed in the lung cancer group and five genotypes in the control group.
  • There was a statistically significant difference in genotype distribution between the lung adenocarcinoma and control group (P=0.0088, A4/A4 vs. non-A4/A4).
  • In the lung adenocarcinoma group, the univariate risk estimates for the A4/A4 subgroup compared to the most common subgroup (A2/A2) was 4.300 (95% confidence interval = 1.358-13.618, P=0.0131).
  • We conclude that the A4/A4 genotype of the 5'-flanking region of CYP2E1 was significantly more frequent in lung adenocarcinoma cases than in healthy controls and, therefore, may be involved in the development of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Cytochrome P-450 CYP2E1 / genetics. Lung Neoplasms / genetics. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142352.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 9007-49-2 / DNA; EC 1.14.13.- / Cytochrome P-450 CYP2E1; M43H21IO8R / Dimethylnitrosamine
  •  go-up   go-down






Advertisement